











The Role of the Arterial Glycocalyx in Sphingosine-1- 
Phosphate Induced Cardioprotection in the Isolated Heart of 







SUBMITTED TO THE UNIVERSITY OF CAPE TOWN 
In fulfillment of the requirements for the degree 
MSc in Medicine (Physiology) 
(HUB 5004W) 
 
Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
 
  Date of submission: 18 December 2017 
  Supervisor:   Dr. Roisin Kelly-Laubscher* 
  Co-supervisors:  Dr. Asfree Gwanyanya 
                                     Dr. Elizabeth van der Merwe                                                     
Department of Biological Sciences* 
Department of Human Biology.    
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 












I, Hala Araibi, hereby declare that the work on which this dissertation/thesis is 
based is original work (except where acknowledgments indicate otherwise) 
and that neither the whole work nor any part of it has been, is being, or is to 
be submitted for another degree in this or any other university. 
I empower the University to reproduce for the purpose of research either the 
whole or any portion of the contents in any manner whatsoever. 
Signature: 






Background: Ischemic heart diseases (IHD) are a leading cause of death 
among cardiovascular diseases. Unfortunately, the myocardial damage due 
to ischemia in IHD may be worsened by reperfusion therapy, a phenomenon 
called ischemic-reperfusion (I/R) injury. Coronary vascular damage is a key 
feature of I/R injury. Among the coronary vascular structures, the endothelial 
glycocalyx is a delicate polysaccharide and protein-rich layer that plays an 
important role in the regulation of vascular permeability, and is easily 
damaged during I/R. Sphingosine-1-phosphate (S1P) is a membrane 
phospholipid metabolite that has been shown to protect the heart against I/R. 
It has also been shown to regulate the synthesis of glycocalyx, but its effects 
on coronary endothelial glycocalyx damage and possible mechanism during 
I/R are unknown. Therefore, we hypothesized that S1P-induced 
cardioprotection is mediated by modulation of the glycocalyx during I/R in the 
isolated rat heart. 
Methods: Isolated male Wistar hearts were perfused on a Langendorff 
system with Krebs-Henseleit buffer via retrograde perfusion at constant 
temperature and pressure. The hearts were stabilized and pre-treated with 
S1P (10 nM for 7 minutes) before inducing 20 minutes of global ischemia, 
followed by 60 minutes reperfusion. Functional parameters were recorded 
throughout the protocol, including left ventricular developed pressure (LVDP), 
left ventricular end diastolic pressure (LVEDP), heart rate (HR) and coronary 
flow (CF). Ventricular infarct size was measured by using triphenyltetrazolium 
chloride stain. Coronary net filtration rate (NFR) was calculated as a ratio of 
the amount of transudate to CF. Cardiac edema was assessed by calculating 
the heart wet/dry weight ratio and histologically quantifying size of the 
interstitial compartment. The shedding of the glycocalyx was estimated by 
measuring the release of the glycocalyx component syndecan-1 in the 
coronary effluent using enzyme-linked immunosorbent assay (ELISA) and 
determining relative syndecan-1 staining intensity between groups in 
immuno-stained wax sections of perfusion-fixed hearts. In addition, the histo-
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morphology of the myocardium was assessed using hematoxylin and eosin 
staining.    
Results: The cardiac performance was depressed after I/R, as was 
reflected by decreased LVDP (P=0.02 vs. control), and an increased LVEDP 
(P<0.0001 vs. control). I/R also significantly increased infarct size (P=0.04 vs. 
control). Treatment with S1P before I/R significantly decreased infarct size 
(P=0.01 vs. I/R), but did not improve the post-ischemic decrease in LVDP or 
stabilize the LVEDP, and had no effect on CF. I/R significantly increased 
release of syndecan-1 in the coronary effluent (P=0.0002 vs. control). 
Immunohistochemically-stained imaging also revealed syndecan-1 staining 
intensity was significantly decreased or absent in ischemic hearts (P≤0.001 
vs. control). Pretreatment with S1P had neither effect on syndecan-1 level in 
the coronary effluent nor on the intensity of syndecan-1 signal in immuno-
stained sections (P=n.s vs. I/R). Histological analysis of cardiac edema 
revealed an increase in the extracellular area in ischemic hearts compared to 
the control hearts (P≤0.001 vs. control), and S1P treatment decreased the 
extracellular area (P≤0.01 I/R+S1P vs. I/R). The NFR, and heart wet/dry ratio 
were not significantly different post-reperfusion between the groups and S1P 
had no effect on these parameters.  
Conclusion: This study showed that pretreatment with S1P protects the 
heart against I/R injury, as was indicated by the decreased infarct size, and 
decreased extracellular cardiac edema. S1P had no effect on hemodynamic 
performance or the shedding of syndecan-1. These results suggest that S1P-
induced cardioprotection is not mediated by protection of the glycocalyx via 
stabilization of syndecan-1. However, it is possible that S1P may stabilize 
other minor glycocalyx components which were not measured in this study, 
such as heparan sulphate and hyaluronic acid. This is the first study that 
evaluated syndecan-1 in the cardiac effluent of the isolated heart of rats with 
global ischemia, and the study opens up prospects for further investigation of 
the role of the glycocalyx in other models of I/R injury, such as the more 
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CHAPTER 1: INTRODUCTION 
 
1.1 Cardiovascular Diseases Major 
 
Cardiovascular diseases (CVD) represent the most common group of non-
communicable diseases and is the leading cause of death worldwide 
(Mathers, Boerma, and Fat 2009). CVD contributed to around 30% of all 
deaths in USA in 2010 (Santulli 2013). However, in 2015, CVD accounted for 
around 17.7 million deaths, amounting to 31% of deaths worldwide and more 
than 75% happen in low- and middle- income countries (WHO 2017). By 
2020, CVD is predicted to be the major cause of morbidity and mortality 
globally (Murray & Lopez 1997). Furthermore, the prevalence of CVD are 
predicted to continue to rise and remain the leading cause of death, 
especially in low- and middle-income countries, such as in Africa by 2030 
(Holmes et al. 2010).  
In sub-Saharan Africa (SSA) there is increasing evidence of a changing 
disease profile, from infectious diseases and nutritional deficiencies to non-
communicable chronic diseases, mainly including CVD (Akinboboye et al. 
2003; Mensah 2008b). CVD caused about one million deaths in 2013 which 
represents 38.3% of non-communicable disease deaths in SSA, and 5.5% of 
global CVD deaths (Mensah et al. 2015). Furthermore, there was a 
significant increase in the number of deaths from CVD in SSA, whereas,  the 
number of deaths due to CVD increased by 81% in 2013, in comparison to 
the deaths that occurred in 1990 (Mensah et al. 2015). In South Africa, non-
communicable diseases contribute to premature mortality and cause around 
39% of deaths, with 44% of these deaths due to CVD (Nojilana et al. 2016).  
This mortality rate may be attributed to the dramatic increase in urbanization 
and the effects of globalization in recent decades; namely, the changes in 
lifestyle such as increased high saturated fat and sugar diets, decreased 
physical activity, high levels of stress and increased tobacco and alcohol 
consumption (Sampson, Amuyunzu-Nyamongo, and Mensah 2013). In 2010, 





the most common leading risk factors of the global burden were 
hypertension, tobacco consumption and air pollution (Stephen et al. 2012). 
However, the number of deaths increased by 41% between 1990 and 2013 
due to CVD globally, and this was mainly caused by  population growth, 
aging, and epidemiological transition (Roth et al. 2015). Furthermore,  It is 
estimated worldwide, that around eight in one hundred cases of  the major 
non-communicable diseases including CVD and  mainly coronary heart 
disease are due to lack of exercise and physical inactivity (Lee et al 2012). 
Other known risk factors for CVD such as hypertension and diabetes are also 
on the rise (Mensah 2008a). Increased blood pressure is the most common 
risk factor associated with CVD (Santulli et al. 2012). It is therefore important 
for public health providers to improve people’s lifestyles and to manage the 
most common preventable risk factors of CVD.   
The most common CVD representing the leading cause of death in the world 
is ischemic heart disease (IHD). IHD caused around 12.7% of total global 
mortality in 2008, with most of these deaths occurring in middle- and low-
income countries. The high mortality in these countries may be due to an 
increase in the prevalence of traditional risk factors for atherosclerotic 
cardiovascular disease (Finegold, Asaria, and Francis 2013). IHD was 
previously considered rare in SSA and remains relatively uncommon.  
However, its incidence and prevalence is increasing and it is expected to 
increase further in the next twenty years, due to the increase in the 
occurrence of risk factors, mainly hypertension, diabetes, obesity and other 
life style changes mentioned above (as reviewed by Onen 2013; Mensah 
2008b). Furthermore, age-standardized mortality rates for IHD  are estimated 
to rise by 70% in African men and 74% in African women by 2030 (as 
reviewed by Onen 2013). 
Myocardial ischemia or IHD is caused by interruption of coronary blood flow, 
due to complete or partial obstruction of the coronary vessels. Prolonged 
ischemia can lead to infarction and irreversible cell damage. Paradoxically, 
although reperfusion of ischemic tissue is important to improve the survival of 
the tissues and prevent irreversible cellular injury, it may lead to more cellular 





damage than that caused by ischemia alone (Yamazaki et al. 1986). This 
type of tissue damage is called ischemia-reperfusion (I/R) injury.  
I/R injury is mainly characterized as a myocardial cell disease, but the 
vasculature also is a major target of the injury (Dignan et al. 1992). Coronary 
vessels are important in delivering the blood and nutrient to the myocardium. 
These vessels are lined by endothelial cell which important in maintaining the 
blood vessel tone, regulating hemostasis, and regulating inflammatory 
processes. Endothelial cells are also coated with a gel-like layer called 
endothelial glycocalyx, which is an important structure that acts as a barrier 
between the vessel wall and circulating blood and maintains the endothelial 
layer integrity. However, the glycocalyx is very delicate and easily damaged 
during I/R injury (Mulivor and Lipowsky 2004). 
 
1.2 The Endothelial Glycocalyx 
 
1.2.1 Structure and Function of the Glycocalyx 
 
The glycocalyx is a thin carbohydrate-rich layer that lines the vascular 
endothelium on the luminal surface. It is an essential structure for vascular 
homeostasis. In dimension, the glycocalyx is about 0.2 – 0.5 µm thick in 
small capillaries and increases in thickness with increasing vascular diameter 
(van den Berg, Vink, and Spaan 2003). The glycocalyx is composed of 
glycoproteins and proteoglycans which act as an important backbone and a 
firm connection to the endothelial cell lining (as reviewed by Reitsma et al. 
2007). Soluble components also represent another important component of 
the glycocalyx, and are present within and on top of the proteoglycan and 
glycoprotein components.  
Proteoglycans are the most important backbone molecules of the glycocalyx. 
These consist of core proteins such as syndecan, glypican, versecan, 
perlican, mimecan and biglycan, with one or more attached negatively 
charged sulphated glycosaminoglycan chains (GAGs), such as heparan 
sulphate (HS), chondroitin sulphate (CS), keratin sulphate (KS), hyaluronic 





acid (HA) and dermatan sulphate (DS). GAGs contribute a negative charge 
to the glycocalyx which allows it to react with the positive charge of albumin 
to give stability to the glycocalyx. The albumin forms part of the permeability 
barrier via electrostatic binding between its positive charged arginine chain 
and the negative charge GAGs of the glycocalyx, and possibly fills the 
intracellular spaces and makes a network which more efficiently filters and 
increases the stability of the glycocalyx (Michel 1985; Adamson and Clough 
1992). The interaction between individual GAG components is independent 
of each other. However, enzymatic removal of one GAG chain does not 
influence other GAGs, and thus will not affect the structural stability of the 
endothelial glycocalyx (Zeng et al. 2012). HS represents the most common 
GAG in the glycocalyx. The second most common is CS, and the rest of the 
glycocalyx is comprised of other GAGs such as KS. Since the proteoglycans 
are named according to their GAG attachment, HS proteoglycan is the most 
common and represents about 50-90% of the total proteoglycans. 
Proteoglycans are sub classified according to their core proteins, with 
syndecan-1 and glypican-1 being the two major HS proteoglycans 
(Rapraeger et al. 1985). 
Syndecan-1 is a member of the syndecan family. There are four types of 
syndecans (syndecan 1-4) and each syndecan consists of a transmembrane 
core protein, with both intracellular and extracellular domains (ectodomain). 
The cytoplasmic and intracellular domains of the four types of syndecan are 
similar in their primary sequences and are considered to have 100% 
homology, but their extracellular domains differ (as reviewed by Zimmermann 
& David 1999). Furthermore, syndecan-1 structure is identical in rats, mice 
and humans in the cytoplasmic domain and transmembrane part, but they 
are different in amino acid sequences of the ectodomain, which exhibits 
around 70% homology between humans and mice, and 88% homology 
between rats and mice (as reviewed by Bernfield et al. 1992). Syndecan-1 is 
expressed in all cell types, mostly in the epithelial cells and maintains 
epithelial cell morphology and normal growth (Leppä et al. 1992). Further, 
syndecan-1 has an important role in the regulation of inflammation, cell-cell 





and cell extracellular interaction (Li et al. 2002), and it can interact with many 
biological effector molecules and participate in regulation of many cellular 
processes, such as cell proliferation, differentiation, migration and cell 
behaviour (Derksen et al. 2002; Sanderson et al. 1994). HA is the only GAG 
not linked to the core proteins and is suggested to have an important role in 
the structure and contribute to the stability of the glycocalyx network 
(Broekhuizen et al. 2009). 
Glycoproteins are also regarded as a backbone component of the glycocalyx 
which connects the glycocalyx to the endothelial cells. Glycoproteins are 
composed of proteins with small-branched carbohydrate side chains, which 
act as adhesion molecules and contribute to the coagulation, fibrinolytic, and 
hemostatic systems. There are three families of adhesion molecules that are 
glycoproteins; the selectin family, the integrin family and the immunoglobulin 
superfamily. The selectin family are responsible for binding of carbohydrate 
groups on the glycosylated proteins or lipids. The integrin family mediates 
endothelial adhesion to leukocytes and platelets. Members of the 
immunoglobulin family are ligands for integrins on leukocytes and platelets 
and mediate leucocyte homing to the endothelium and subsequent 
diapedesis (as reviewed by Reitsma et al. 2007). Soluble components are 
another important part of the glycocalyx. These include soluble proteins 
derived from blood or endothelium such as albumin and orosomucoid, which 
are incorporated between and cover the top of the proteoglycan-glycoprotein 
network and contribute in functional properties of the glycocalyx (Sörensson 
et al. 1999). 
The glycocalyx provides essential functions necessary for vascular 
homeostasis. It regulates the permeability in peripheral vessels due to its 
negative charge, which antagonizes positively charged molecules and 
prevents certain molecules from passing through the endothelial cell 
membrane (van Haaren et al. 2003; van den Berg et al. 2003). Besides, the 
glycocalyx thickness in the vessel wall is enough to acts as a physical barrier 
between the cell adhesion molecules such as P-selectin and blood cells 
(Patel et al. 1995), thus it prevents adhesion of leukocytes and platelets to 





endothelial cells (Mulivor and Lipowsky 2002). Recently, several studies have 
suggested that the glycocalyx can act as a mechanotransducer. Glycocalyx 
structures can convert the shear stress force of blood flow into shear-
dependent endothelial responses, including vasorelaxation mediated by nitric 
oxide (NO), which is released from endothelial cells when exposed to shear 
stress (Gouverneur et al. 2006; Kelly et al. 2006; Tarbell and Pahakis 2006). 
Furthermore, the glycocalyx is suggested to play a role in the regulation of 
coagulation pathways, as many mediators which control the coagulation 
pathways are bound to the glycocalyx (Ho et al 1997). Finally, the glycocalyx 
can bind to the extracellular superoxide dismutase enzyme which can 
decrease oxidative stress by quenching oxygen free radicals and increase 
NO bioavailability (Li et al. 1998). 
The function of the glycocalyx is dependent on the structural integrity of the 
glycocalyx and the health status of blood vessels. The disruption of the 
glycocalyx leads to failure of its function and the occurrence of pathological 
events such as increased endothelial permeability, edema formation, 
increased platelets, leukocyte aggregation and adhesion to the vessel wall, 
and hypercoagulation. Pathological conditions that can lead to glycocalyx 
damage include I/R injury (Rubio-Gayosso et al. 2006), diabetes mellitus 
(Zuurbier et al. 2005), sepsis (Hofmann-kiefer and Kemming 2009), 
hyperlipidemia (Vink et al. 2000), hypervolemia (Chappell et al. 2014) and 
severe trauma (Rahbar et al. 2015). 
1.3 Ischemia-Reperfusion Injury: Mechanism, Types, and 
Clinical Relevance. 
 
The mechanisms of I/R injury are still not clear but there are molecular and 
cellular events that occur during ischemia and reperfusion that are suggested 
to be responsible for this type of damage (Figure 1). 






Figure 1: Suggested cascade of events in ischemia-reperfusion injury that 
may be linked to glycocalyx damage. Mitochondrial permeability transition 
pore (mPTP), reactive oxygen species (ROS). 
Ischemia leads to a shortage of oxygen supply to the cardiac tissue, resulting 
in hypoxia. Hypoxic cells will undergo oxidative stress which results in cellular 
metabolic and ultra-structural changes, leading to failure to synthesize 
energy-rich phosphates, including adenosine-triphosphate (ATP) and 
phosphocreatine. Anaerobic metabolism and depletion of ATP may result in 
acidosis and alteration of membrane pump functions, resulting in disturbance 
of the ionic state across the cell membrane (Van Emous et al. 1998). The 
most important ionic disturbances are increased entry and accumulation of 
sodium, and water into the cell and depletion of potassium, which can lead to 
osmotic swelling and sarcolemmal membrane rupture, leading to necrosis 
(van Emous et al. 1997). In addition, intracellular calcium increases due to 
oxidative stress and disturbances in ion transport systems in the 
sarcolemmal membrane. Accumulation of calcium in cardiac cells leads to 
hypercontraction of heart cells and damage to mitochondria (Tani and Neely 
1989). Further injury and cell death will be caused by the activation of 
calcium-dependent proteases with ongoing ischemia. Reperfusion of the 
ischemic tissue will end the ischemic changes, but reperfusion itself leads to 





more damage, as sudden introduction of oxygen to the tissues will lead to 
increased production of toxic free radicals which lead to cellular injury by 
reaction with  proteins, nucleic acid, and lipids (Paradies et al. 1999). 
Accumulation of toxic reactive oxygen species (ROS) occurs early during 
reperfusion of ischemic tissue (Garlick et al. 1987). These molecules are 
short-lived, unstable, highly reactive, and generated in small amount during 
mitochondrial respiration, activation of phagocytic cells and xanthine oxidase 
activity. The normal produced ROS are inactivated by endogenous 
scavenging systems; however, in I/R injury production of free radicals 
increases and overwhelming the intracellular free radical scavenger system 
and results in accumulation of these molecules and cell damage (Zweier 
1988). All these metabolic and ionic changes, combined with accumulation of 
toxic catabolites, result in more osmotic swelling which is sufficient to cause 
sarcolemmal membrane rupture and cell damage.  
The mitochondrial permeability transition pores (mPTP) also play a significant 
role in the mechanism of reperfusion injury. These pores are situated in the 
inner mitochondrial membrane, and are impermeable to all metabolites and 
ions under normal physiological conditions. Accumulation of calcium and 
ROS during reperfusion leads to prolonged opening of mPTP, resulting in 
influx of solutes and water to the mitochondrial matrix (Halestrap et al. 1998; 
Crompton, Costi, and Hayat 1987). Furthermore, mitochondrial swelling and 
rupture lead to release of pro-apoptotic factors such as cytochrome c, which 
leads to activation of the caspase cascade and results in mitochondrial 
dysfunction, which initiates the mitochondrial apoptosis pathway and cell 
death (Moissac et al. 2000; Barauskaite et al. 2011)  
Activation and accumulation of leukocytes in the damaged myocardium occur 
shortly after reperfusion, and promote the expression of adhesion molecules. 
Activated neutrophils become adherent to the endothelial cells leading to an 
increase in the release of cytotoxic and chemotactic substances such as 
cytokines, proteases, leukotrienes and oxygen free radicals which lead to 
endothelial damage, increase vascular permeability and thrombosis (Romson 





et al. 1983; Baxter 2002). There is also evidence that neutrophils stimulate 
platelet activation and together exacerbate the post reperfusion cardiac 
contractile dysfunction (Lefer et al. 1998). Complement system activation 
also can occur as result of I/R injury, leading to stimulation of inflammatory 
cells and production of several inflammatory mediators which increase cell 
permeability, release of histamine, and platelet activating factor resulting in 
direct cell injury (Weiskopf et al. 2001).  
Coronary endothelial dysfunction can occur as a consequence of I/R injury.  
The endothelium is representing the major source of NO, which leads to 
vasodilation, decreased platelet aggregation and decreased neutrophil 
adherence (Jones et al. 1999; Davenpeck et al. 1994), this function will be 
impaired after reperfusion due to hypoxia and ROS production. Impairment of 
the endothelial cell function manifests as impaired endothelial-dependent 
vasodilation and increased response to vasoconstrictors, resulting in 
decreased blood flow to the tissues (Tsao et al. 1990; Nakanishi et al. 1994). 
All this inflammatory cell activation and the release of its inflammatory 
mediators will compromise the integrity of the endothelial barrier, which 
includes the endothelial glycocalyx (Rubio-gayosso et al. 2006) and can lead 
to increases in vascular permeability and tissue edema. 
The glycocalyx layer is stable under normal physiological conditions, which 
results from a balance between biosynthesis and shedding of its components 
(Mulivor and Lipowsky 2004). However, many studies in the isolated heart 
model have demonstrated that 20 minutes of no-flow ischemia with 
reperfusion is enough to cause degradation of the glycocalyx layer (Chappell 
et al. 2009a; Bruegger et al. 2008). Clinical studies have also demonstrated 
the shedding of glycocalyx components such as syndecan-1 and heparan 
sulphate in blood samples from patients who undergo vascular surgery with 
global or regional ischemia, and coronary bypass surgery (Rehm et al. 2007). 
The mechanisms related to shedding of the glycocalyx in I/R injury are not 
clear, but production of ROS during I/R has been proposed to play an 
important role (Rubio-gayosso, Platts, and Duling 2006). Activation of 
inflammatory cells and macrophages after I/R may also be responsible for 





increased shedding, by increasing the production of ROS and other 
degrading enzymes such as heparanases, and neuraminidase. Tumour 
necrosis factor-α (TNF-α) is released as a result of inflammatory stimuli, such 
as ischemia, and has been shown in many studies to disrupt the barrier 
properties of the glycocalyx layer. TNF-α may cause activation of leukocytes, 
which then liberate cytokines, proteases and other factors which may disrupt 
the glycocalyx. TNF-α also has the ability to stimulate the endothelium 
directly to shed glycocalyx components (Henry and Duling 2000; Chappell et 
al. 2009b).  
Post-ischemic hypoxia can also lead to decreased activity of adenylate 
cyclase, and intracellular cAMP levels resulting in decreased endothelial 
barrier function and increased permeability (Ogawa et al. 1992). The degree 
of endothelial barrier injury is increased in proportion to the duration and the 
severity of ischemia (Dauber et al. 1990). Myocardial edema after I/R injury is 
not stable and follows a bimodal pattern. The first one occurs directly after 
reperfusion, disappears at 24 hrs and then starts to increase progressively to 
reach maximum levels at day 7 (Fernandez-Jimenez, Sanchez-Gonzalez, et 
al. 2015). The first wave of edema occurs due to the reperfusion process 
itself and, the second wave occurs due to the tissue healing process 
(Fernandez-Jimenez, Garcia-Prieto, et al. 2015).     
The severity of the cell damage and death is determined by many factors, 
including the type of ischemia (whether global or regional) and the duration of 
ischemia. Global ischemia is caused by complete severing of the blood 
supply to the entire heart. Regional ischemia is caused by obstruction of 
coronary arteries and only the part of the myocardium perfused with this 
artery will become ischemic.  
From experimental studies on the effects of both types of ischemia on the 
myocardium, it is suggested that global ischemia leads to significant 
depression of cardiac function, and more significant tissue infarction in 
comparison to regional ischemia (Kim et al. 2012). Moreover, the severity of 
myocardial injury after I/R is adversely related to the duration of ischemia 





itself - either regional or global ischemia. A shorter duration of ischemia (<20 
minutes) may not be sufficient to cause irreversible damage to the myocytes, 
but it can lead to contractile and bio-energetic dysfunction which is markedly 
depressed with an increased duration of ischemia (>20 minutes), and the 
affected cells become irreversibly damaged. Bibli et al. (2012) assessed the 
effect of different durations of both types of ischemia on the functional 
recovery of the isolated rat heart. They found that a longer duration of 
ischemia was associated with more tissue damage and post ischemic 
ventricular dysfunction, which was more prominent after global than regional 
ischemia. Palmer et al. (2004) have shown the effect of different durations of 
global ischemia in isolated perfused rat hearts. They stated that the post 
ischemic dysfunction changed from mild to severe after 20 minutes of global 
ischemia. However, the left ventricular function was mildly weakened after an 
ischemic duration of 20 minutes or less, when compared with longer 
ischemia. Long duration of ischemia >20 minutes leads to an increase in end 
diastolic pressure, decreased coronary flow, and increases of creatine kinase 
release which is an indication of the severity of irreversible myocyte injury. In 
addition, prolonged ischemia can cause a significant edema formation and 
abnormality in the mitochondrial appearance with markedly swollen of the 
cristae and decreases in matrix density. 
Clinically, regional ischemia is the most common type of myocardial ischemic 
episode. Regional ischemia occurs during thrombolysis, percutaneous 
coronary interventions, and coronary bypass. However, global ischemia also 
occurs in humans during open heart surgery when the aorta is clamped or in 
cardiac arrest. Revascularization of global or regional ischemic tissue leads 
to reperfusion injury which is manifested by myocardial stunning (Heyndrickx 
et al. 1975). This condition is defined as "prolonged post ischemic 
mechanical dysfunction that persists after reperfusion of previously ischemic 
tissue, without irreversible damage, and leads to unstable hemodynamic 
conditions". In addition, repeated episodes of stunning may lead to 
cardiomyopathy and heart failure (Renkin et al. 1990). Myocardial stunning is 
caused by calcium overload or generation of oxygen free radicals. Other 





manifestations of reperfusion injury are reperfusion arrhythmias which 
include ventricular tachycardia and ventricular fibrillation which may lead to 
cardiac arrest and sudden death (Yamazaki et al. 1986). Endothelial 
dysfunction, myocyte death and necrosis can also occur after reperfusion 
injury. 
1.3.1 Therapeutic Strategies for I/R Injury 
 
The therapeutic strategies that limit I/R injury include ischemic conditioning 
and pharmacological interventions. Ischemic conditioning is a result of 
inducing one or more short episodes of ischemia interspersed with periods of 
reperfusion, either before the prolonged ischemia (a protocol called ischemic 
preconditioning; IPC) or after prolonged ischemia (a protocol called post 
conditioning; IPOST). Ischemic conditioning can also protect the heart if short 
ischemia-reperfusion episodes are applied to another organ distant from the 
heart before the heart is exposed to prolonged ischemia. This is protocol is 
called remote ischemic conditioning.  
IPC was first described in the dog heart by Murry et al. (1986), and they 
suggested that IPC can decrease infarct size and improve functional 
recovery. Moreover, IPC preserves vascular endothelial function (Coulson et 
al. 1997), reduces apoptosis by inhibiting neutrophil accumulation (Nakamura 
et al. 2000), preserves cellular structure, and delays the development of 
structural signs related to ischemic injury (Murry et al. 1990). The mechanism 
of IPC and IPOST have not been well understood. However, there are many 
studies suggesting that different triggering substances are involved in 
mechanisms of ischemic conditioning pathways, which may lead to 
decreased production of ROS, decreased mitochondrial calcium overload 
(Wang et al. 2001), improved endothelial function and inhibition of the 
opening of the mPTP (Javadov et al. 2003; Argaud et al. 2005). Ischemic 
conditioning also activates prosurvival kinases involved in the reperfusion 
injury salvage kinase (RISK) pathway (Hausenloy et al. 2005) and the 
survivor activating factor enhanced (SAFE) pathway (Lacerda et al. 2009; 
Somers et al. 2012), which include various signaling pathways activated at 





the time of reperfusion in both IPC and IPOST mediated cardioprotection. 
The cardiac protection achieved with IPC provides the same benefits as 
IPOST (Zhao et al. 2003). The mechanism underlying the remote 
conditioning are not fully understood and may overlap with those of IPC or 
IPOST. In addition, mechanisms involving neural or humoral pathways have 
been proposed in remote ischemic conditioning (Lim, Yellon, and Hausenloy 
2010). 
Pharmacological conditioning refers to cardiac protection by using 
pharmacological agents, which have been demonstrated in experimental 
studies to reduce myocardial infarction. The mechanism of pharmacological 
agents is to mimic the mechanistic pathway of ischemic conditioning. Some 
of these agents induced cardioprotection via enhancement of parts of the 
RISK pathway. These agents include adenosine (Liu et al. 1991), atrial 
natriuretic peptide (Kitakaze et al. 2007), bradykinin (Wall et al. 1994) 
atorvastatin (Bell and Yellon 2003) and erythropoietin (Chong et al. 2002). 
Others are mediated via the SAFE pathway, such as sphingosine-1-
phosphate (S1P) (Kelly-Laubscher et al. 2014), and ethanolamine (Kelly et 
al. 2010). In addition, cyclosporine A induced cardioprotection is mediated by 
preservation of mitochondrial function during reperfusion (Skyschally, Schulz, 
and Heusch 2010). Recently, other agents such as antithrombin (Chappell et 
al. 2009a) and hydrocortisone (Chappell et al. 2007), have been shown to 
induce cardioprotection mediated by preservation of the endothelial barrier 
and decreased endothelial glycocalyx damage during I/R.   
1.3.2 Pharmacological Protection of the Glycocalyx 
Many agents have been shown in animal studies to protect the glycocalyx. 
These agents, such as glucocorticoids which have anti-inflammatory 
properties, are suggested to reduce the oxidative stress and glycocalyx 
damage and can limit the damage caused by inflammation and I/R (Chappell 
et al. 2007; Chappell et al. 2009b). Antithrombin is a potent anticoagulant and 
has remarkable anti-inflammatory properties. It has been demonstrated to 
protect the endothelial glycocalyx in animal models of I/R injury (Chappell et 





al. 2009a). Sevoflurane is a volatile anesthetic agent which protects the 
glycocalyx against I/R and maintains the natural coating of endothelial 
adhesion molecules and reduces cell adhesion by attenuation of lysosomal 
cathepsin B release (Annecke et al. 2010; Chappell et al. 2011). Nitric oxide 
can also protect the heart after I/R injury - it prevents coronary vascular leak 
and tissue edema post ischemic injury by preserving the glycocalyx layer 
(Bruegger et al. 2008). Moreover, there are studies in non-ischemic animal 
models which suggest restoration of the glycocalyx after shedding by infusion 
of glycocalyx components (Constantinescu, Vink, and Spaan 2003; Henry 
and Duling 1999). Sphingosine-1-phosphate (S1P) has been known as a 
potent cardioprotective agent against I/R injury. Recently, S1P has been 
shown that can protect the glycocalyx against shedding in isolated cells 
against a non-ischaemic insult (Zeng et al. 2014) and promoting the 
synthesis of glycocalyx to maintains endothelial permeability (Zeng et al. 
2015). However, whether this protection exists in a whole organ, or whether 
S1P can decrease glycocalyx shedding during I/R, is unknown. 
1.4 Sphingosine-1- Phosphate 
 
1.4.1 Structure and Function 
S1P is a bioactive sphingolipid metabolite. It is one of the metabolic products 
of sphingomyelin and other phospholipid precursors by sphingosine kinase 
stimulation (as reviewed by Pyne & Pyne 2000). It is important in the 
regulation of many biological processes and cellular responses. S1P is 
produced and secreted by many cells including red blood cells, platelets, 
epithelial cells and cardiomyocytes. Platelets are suggested to be the 
greatest source of extracellular S1P, because they possess a highly active 
sphingosine kinase and lack the degrading enzyme S1P lyase (Yatorni et al. 
1995). However, other studies suggest that red blood cells are the major 
source of S1P (Bode et al. 2010; Adamson et al. 2014).  
S1P concentration in the plasma and serum ranges from 0.3 - 0.5 µM, and 
about 90% is bound to serum proteins, mainly high density lipoproteins 





(HDL), serum albumin and low density lipoproteins (Murata et al. 2000) and 
these carry it to the endothelial cells to maintain the vascular permeability 
(Adamson et al. 2014). S1P is lipophilic and has been shown to bind with 
serum proteins, and these proteins may trap S1P and reduce its binding to its 
receptors. Therefore, the effective or active concentration of S1P in plasma 
might be much lower than total amount of the S1P in the plasma (Murata et 
al. 2000). On the other hand, S1P concentration in the plasma depends on 
plasma albumin concentration, and any condition that leads to decreased 
plasma albumin concentration may affect S1P level and compromise 
endothelial permeability. Moreover, the stability of the glycocalyx structure as 
part of the endothelial barrier is dependent on the plasma albumin 
concentration. In particular, removal of plasma proteins leads to decreased 
S1P delivery to the glycocalyx layer and increased protease dependent 
shedding of the glycocalyx and increased vascular permeability (Zeng et al 
2014). Endothelial cells also represent another source of S1P 
(Venkataraman et al. 2008), however, experimental studies have concluded 
that S1P delivered from endothelium is not enough to maintain permeability 
and experiments on cultured endothelium or isolated vascular segment need 
a perfusate which saturated with S1P or source of S1P.       
S1P has two sites of action: intracellular and extracellular. It acts 
intracellularly as a second messenger in the regulation of calcium 
homeostasis, and suppresses apoptosis via inositol trisphosphate-
independent mechanisms (Mattie, Brooker, and Spiegel 1994). However, the 
target of intracellular S1P is still uncertain; it may act directly in the nucleus 
and influence gene expression. Alternatively, some evidence suggests that 
S1P can increase the release of calcium from intracellular sources by an 
inositol trisphosphate-independent pathway (Mattie, Brooker, and Spiegel 
1994). Extracellular actions of S1P are mediated through activation of G-
protein coupled cell surface receptors called S1P receptors (S1P1-5) (Hla 
2001). Cardiomyocytes express S1P1, S1P2 and S1P3 receptors and 
activation of these receptors affect cardiac contractility and heart rate (Means 
et al. 2008; Mazurais et al. 2002). S1P1 receptor is the most abundantly 





expressed on endothelial cells and contribute to maintain vascular barrier 
integrity (Zhang et al. 2010). Also, activation of S1P1 receptor by 
endogenous S1P regulates intracellular calcium levels by maintaining activity 
of the sarcolemmal Na/H exchanger and its activation is required for the 
cardioprotective effect of S1P in IPC (Keul et al. 2016).   
S1P is found in many systems and is suggested to be involved in the 
physiological regulation of such systems. In the vascular system, S1P acts as 
a strong regulator of angiogenesis and may act as a vasoconstrictor or a 
vasodilator, depending on the expression pattern of S1P receptor sub-type in 
endothelial cells and vascular smooth muscles (Coussin 2002; Ohmori et al. 
2003). In the immune system S1P is expressed in multiple immune cells and 
regulates their functions, and the S1P analogue FTY720 fingolimod (2-
amino-2[2-(4-octylphenyl) ethyl] propane-1,3-diolhydrochloride), is suggested 
from immunomodulation studies to be an effective drug in the treatment of 
autoimmune diseases such as multiple sclerosis (Kappos 2006). S1P acts 
intracellularly as a second messenger to regulate cell growth (Zhang et al. 
1991). Further, S1P can regulate functions of other systems such as the 
nervous and reproductive systems (Hla 2004). 
1.4.2 Role of S1P in Cardiovascular Protection 
 
Many studies have demonstrated the role of S1P in cardioprotection. S1P 
represents as one of the endogenous mediators released from 
cardiomyocytes during IPC and IPOST and can limit I/R-induced myocardial 
injury. Evidence for this comes from experiments where the S1P inhibitor, 
VPC, inhibited protection induced by both types of ischemic conditioning 
(Vessey et al. 2009). During ischemic conditioning, the released S1P leads to 
activation of S1P1 and S1P3 receptors and triggers cell-signalling pathways 
which induce cardioprotection. These signalling pathways include the 
activation of signal transducer and activator of transcription-3 (STAT3) and 
TNF-α which are involved in SAFE pathways, as well as the activation of 
protein kinases Akt and ERK, which are involved in the RISK pathway (Jin, 
Karliner, and Vessey 2008). IPC and IPOST lead to activation of protein 





kinase C epsilon (PKCє) by releasing of mediators, PKCє in turn increases 
the activity of sphingosine kinase which is an important intracellular mediator 
leads to increase synthesis of S1P induced cardioprotection after I/R (Jin, 
Goetzl, and Karliner 2004).  
S1P also is known as exogenous cardioprotectant agent which can protect 
the heart from I/R injury. Karliner et al. (2001) were the first to demonstrate 
the role of exogenous S1P in cardioprotection. They demonstrated that 
pretreatment with S1P reduced hypoxic cell death in cultured neonatal rat 
cardiac myocytes. In this study, the cardioprotective effect of S1P was 
mediated by protein kinases C and mitochondrial KATP channels. A 
subsequent study demonstrated that S1P protects cardiomyocytes from I/R 
injury, via activation of both S1P2 and S1P3 receptors through activation of 
an Akt-mediated pathway (Means et al. 2007). Furthermore, S1P 
pretreatment of hearts isolated from PKCє knockout mice and wild-type 
subjected to I/R injury, induced cardioprotection through a signalling that was 
independent of PKCє (Jin et al. 2002). Additional evidence for the role of S1P 
in cardioprotection comes from Theilmeier et al. (2006) who showed that 
infusion of HDL which is rich in S1P can reduce cardiac damage induced by 
I/R injury via S1P3 receptor-mediated and NO-dependent pathway. Other 
mechanisms suggested for the role of S1P-induced cardioprotection against 
I/R damage are through activation of both SAFE and RISK pathways after 
pharmacological pre- or post-conditioning of isolated heart with S1P (Kelly-
Laubscher et al. 2014; Somers et al. 2012). Also, the S1P can induce 
cardioprotection via activation of STAT3 as part of SAFE pathways and this 
protection was mediated by ethanolamine which is a product of S1P 
metabolism (Kelly-Laubscher et al. 2010).  
The cardioprotective effects of synthetic S1P receptor agonists such as 
S1P1,3 receptor agonist FTY720 and selective S1P1 receptor agonist 
SEW2871 also have been demonstrated and they are thought to act via Akt 
activation when applied during reperfusion (Hofmann et al. 2009). Moreover, 
FTY720 can prevent arrhythmia induced by I/R injury through PaK1/Akt 
signalling (Egom et al. 2010).  Pretreatment with FTY720 before ischemia 





can also reduce post ischemic arrhythmia and decrease leukocyte infiltration 
with no effect on the infarct size. However, treatment during reperfusion 
increased mortality due to induction of arrhythmias, and it is suggested that 
FTY720 is an ideal preconditioning drug but not a post conditioning drug 
(Hofmann et al. 2010). 
S1P has been identified as an important regulator and enhances the 
endothelial barrier function (Curry, Clark, and Adamson 2012). S1P can 
inhibit increased vascular permeability induced by inflammatory mediators 
such as platelet activating factor and bradykinin, which are released mainly 
during inflammatory conditions and leads to increased endothelial 
permeability and edema. This protection was mediated by activation of S1P1 
receptor (Zhang et al. 2010). In addition, HDL which is the main carrier of 
S1P in the plasma, promotes endothelial barrier integrity, and these 
protective effects are suggested to be attributed to its S1P component and 
S1P1/Akt signalling (Argraves et al. 2008). Other mechanisms by which S1P 
can enhance the endothelial barrier is by phosphorylation of focal adhesion 
kinase which is important in actin cytoskeletal rearrangement, as well as 
increased cell-cell adhesion junctions (Shikata, Birukov, and Garcia 2003). 
S1P can also maintain endothelial barrier function in normal intact vessels by 
protecting the endothelial glycocalyx layer via activation of S1P1 receptors 
(Zhang et al. 2016). Also, S1P has been shown to protect the endothelial 
glycocalyx against shedding, after removal of plasma albumin in rat fat pad 
endothelial cells, through suppression of metalloproteinase (MMP) activity via 
activation of the S1P1 receptor (Zeng et al. 2014). Inhibition of MMPs 
protected against loss of chondroitin sulphate and syndecan-1 (Zeng et al. 
2014). Furthermore, S1P can regulate and induce synthesis of glycocalyx 
components in rat fat-pad endothelial cells, after their shedding and this was 
mediated by phosphoinositide 3-kinase (PI3K) pathway (Zeng et al. 2015). 
However, this ability of S1P to stabilize and replenish the endothelial 
glycocalyx has not been shown in a whole organ model in the context of I/R 
injury. 








We hypothesize that pretreatment with sphingosine-1-phosphate decreases 





To assess whether the cardioprotective effect of sphingosine-1-phosphate 
against ischemic-reperfusion damage in the isolated rat heart model is 




1. To confirm that I/R injury leads to increased degradation of the 
endothelial glycocalyx in addition to other molecular- and structural 
changes in the isolated rat heart model. 
 
2. To assess the effects of sphingosine-1-phosphate on the degradation 
of the glycocalyx, infarct size, and cardiac edema during ischemia-
reperfusion in the isolated rat heart. 
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Adult male Wistar rats (weight 250 - 300 g) were used in the experiments. All 
rats were transferred from Stellenbosch University to the Anatomy Building 
HUB basement at the University of Cape Town, where they were allowed to 
acclimatize to a new environment for two days before starting the 
experimental procedures. The rats were kept under controlled conditions 
(room temperature 21 - 23 οC and light intensity 150 lux), with free access to 
standard rat chow (Imbani Nutrition, SA) and water. 
All experiments were approved by the Faculty of Health Sciences Animal 
Ethics Committee, University of Cape Town (Protocol AEC REF NO: 
014/012), and performed in compliance with the Guide for the Care and Use 
of Laboratory Animals published by the US National Institutes of Health 
(National Research Council, National Press 2011). All the laboratory animal 
procedures were authorized by the South Africa Veterinary Council (SAVC) 
(NO: AR15/13426).  
 
3.2 Experimental Design 
A total of 117 rats were used in this study. Twelve rats were used in 
preliminary tests; two were used to train the procedure of perfusion and 10 
were used to optimize the I/R protocol. Seventy-three rats were used to 
collect the data and divided into four groups (N≥16 rats per group), according 
to the Langendorff perfusion protocols further described below. At the end of 
reperfusion, each group was divided into three sub groups for; 
triphenyltetrazolium chloride (TTC) staining to assess infarct size, heart 
weight wet/dry ratio to assess cardiac edema, and histological investigation 
to assess syndecan-1 and extracellular edema (Figure 2). An additional 
group was included to assess the effects of Krebs-Henseleit buffer (K-H) 
perfusion alone on cardiac edema (N=7). Thirty-two rats were excluded from 
the study because they either did not comply with the inclusion criteria (see 
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section 3.3.2) or other reasons such as difficulties in cannulation or the heart 












3.3 Isolated Rat Heart Model 
3.3.1 Heart Isolation and Langendorff Perfusion 
Male Wistar rats were weighed and anesthetized with sodium pentobarbitone 
(70 mg/kg, i.p.), with co-administration of heparin (500 IU) to reduce 
thrombus formation. Once the pedal withdrawal reflex disappeared, the chest 
cavity was opened through a skin incision performed at the xiphoid–sternum 
end and continued to lateral anterior axillary lines. The anterior chest wall 
was deflected upward and the pericardium opened. The heart was excised 
rapidly, arrested in cold K-H (4 οC), and mounted on the Langendorff 
retrograde perfusion system via cannulation of the aorta (Figure 3). 
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Figure 2: Experimental design. Four groups of rats were used. At the 
end of the protocol, each group was divided to three sub groups, one 
for TTC staining to assess infarct size (N≥6 each group), one for 
measurement of heart weight wet/dry ratio to assess cardiac edema 
(N=7 each group), and one for histological assessment of syndecan-1 
and edema (N=3). A group of K-H perfusion only (N=7) were added to 
assess cardiac edema.  
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The hearts were perfused with K-H buffer (in mM 118.5 NaCl, 25 NaHCO3, 
4.7 KCl, 1.2 KH2PO4, 1.8 CaCl2, 1.2 MgSO4, 11 glucose, pH 7.4), bubbled 
with 95% oxygen and 5% carbon dioxide throughout the protocol (Appendix 
1). The perfusion pressure was kept constant at 74 mmHg by placing the K-H 
reservoir at a height of 1 meter above the tip of the perfusion cannula. The 
temperature of the perfusate was kept constant throughout the protocol at 37 
οC, by using water-jacketed reservoirs and a heat exchanger.  
A water-filled ventricular balloon was inserted through the left atrium into the 
left ventricle and was connected to a calibrated pressure transducer 
(MLT0699, ADInstruments, Australia) by polyethylene tubing. This transducer 
was connected to a Power Lab 4/30 data acquisition system (ADInstruments, 
Australia) via a Bridge Amplifier (ML221, ADInstruments, Australia) to 
measure the hemodynamic parameters. The data were recorded and 
digitized using Lab chart software version 7.00 (ADInstruments). The left 
ventricular end diastolic pressure was adjusted between 4 and 12 mmHg at 
the beginning of protocol. The pulmonary artery was cannulated to allow 
coronary venous effluent to be collected for measurement of coronary flow 
rate and syndecan-1. 
 
Figure 3: Langendorff retrograde perfusion. (A) Langendorff retrograde 
perfusion apparatus. (B) Langendorff retrograde heart perfusion technique. 
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3.3.2 Exclusion Criteria 
The rat hearts that did not comply with the following criteria at baseline were 
removed from the study (N=32 rats): 
Criterion Inclusion Parameter 
Heart rate 
 
240-400 beat per minute 









3.3.3 Langendorff Perfusion Protocol 
In preliminary experiments, the duration of global ischemia was optimized 
with the aim to achieve functional recovery upon reperfusion. Global 
ischemia was induced by stopping the perfusion flow by closure of a three-
way tap above the aortic cannula and reperfusion was induced by restoring 
the flow. During ischemia, the temperature of the heart was maintained at 37 
οC by immersing it in a warm K-H buffer bubbled with oxygen and carbon 
dioxide. Three different durations of global ischemia were used: 20, 25 and 
30 minutes. We found that only hearts subjected to 20 minutes ischemia 
recovered during reperfusion, and this duration of ischemia was selected in 
our ischemia-reperfusion model (Appendix 2 and 3).  
During Langendorff perfusions, all hearts were stabilized for 20 minutes and 
then divided according to treatment and induction of global ischemia (Figure 
4) as follows:  
Control group: Hearts were infused with the vehicle dimethylsulphoxide 
(DMSO) (1:10000 diluted in K-H) for 7 minutes, and then perfused with K-H 
for 90 minutes.  
I/R group: Hearts were infused with DMSO for 7 minutes, followed by 10 
minutes washout, and then exposed to 20 minutes global ischemia and 1 
hour reperfusion. 
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I/R +S1P group: Hearts were infused with S1P (10 nM) for 7 minutes, 
followed by 10 minutes washout (Kelly-Laubscher et al. 2014; Lecour et al. 
2002), and then exposed to 20 minutes global ischemia and 1 hour 
reperfusion. 
S1P group: Hearts were infused with S1P (10 nM) for 7 minutes and then 
perfused with K-H for 90 minutes. 
An infusion pump (Graseby 2100, Medical Smith, UK) was used to infuse 
S1P and DMSO to the heart through a 3-way tap connected to both the aortic 
cannula and K-H reservoir. The infusion speed was adjusted to 1/10 of the 







                  
Figure 4: Schematic representation of Langendorff perfusion protocol. 
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3.4 Hemodynamic Measurements 
 
Various cardiac parameters were measured throughout the experiment, 
including left ventricular systolic pressure (LVSP), left ventricular end 
diastolic pressure (LVEDP), heart rate (HR), coronary flow (CF) and left 
ventricular developed pressure (LVDP: difference between left ventricular 
systolic and left ventricular end diastolic pressure). Rate pressure product 
(RPP) was calculated as LVDP × heart rate, and functional recovery was 
expressed as percentage of baseline. Coronary flow rate was measured by 
timed collection of coronary effluent through cannulation of the pulmonary 
artery. The transudate was collected from the apex of the heart and net 
filtration rate (NFR) was calculated as the ratio between the transudate and 
effluent flow rate. 
3.5 Infarct Size Analysis 
 
Staining with TTC was used to differentiate necrotic cardiac cells from viable 
cells. At the end of the perfusion protocol, the hearts were decannulated and 
frozen at -20 οC. Once frozen they were sectioned to slices of 2 mm 
thickness, perpendicular to the long axis, and incubated in 1% TTC in 
phosphate buffer at 37 οC (pH 7.4) protected from light for 20 minutes. Slices 
were fixed in 10% formalin solution in a dark cupboard at room temperature, 
for clearer delineation between the viable (red), and non-viable (pale) tissue. 
After 24 hours, the heart slices were arranged from apex to base between 
two transparent plates and digitally scanned on a flat- bed scanner 
(CanoScan LDE 110, Vietnam). Total tissue area and infarct area were 
measured using ImageJ software (ImageJ, NIH Image) for the details of 
measurement (see Appendix 5). Infarct size was expressed as percentage of 
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3.6 Assessment of Cardiac Edema 
Measurement of cardiac edema was obtained by calculating the wet/dry 
heart weight ratio. At the end of each protocol, the hearts were decannulated 
and weighed to obtain wet weight. The hearts were then placed in an oven at 
60 οC for 24 hours and weighed again to obtain dry weight. These values 
were used to calculate wet/dry heart weight ratio. 
In this analysis, another group of rats were added to investigate the effect of 
DMSO on the cardiac edema. This group was perfused with K-H only for the 
same duration as other protocols and coronary effluent was collected for 
analysis of syndecan-1 levels. 
Further, histological investigation was added to assess cardiac edema by 
quantification of the extracellular edema (see sections 3.8, and 3.8.2). 
3.7 Determination of the Glycocalyx Components 
 
3.7.1 Sample Collection and Preparation 
 
The samples of coronary effluent were collected from all groups, through the 
cannulated pulmonary artery over 10 minutes at 0 – 10 minutes after onset of 
reperfusion (Annecke et al. 2010), then kept at -20 οC. Once all perfusion 
experiments were completed, coronary effluent samples were defrosted and 
centrifuged. Samples of 2 ml each were concentrated to 150 – 200 µL with 
10 KDa cut-off ultrafilters centrifugal unit (Millipore, Billerica, MA, USA), using 
Eppendorf centrifuge (5810/5810 R Swing- bucket rotor centrifuge, 
Eppendorf, Germany), at 2020 × g at room temperature (20 οC) for 1 hour. 
Thereafter, samples were aliquoted and frozen at -80 οC until used for ELISA 
(Annecke et al. 2010).  
The samples were collected in a series over one year. However, samples 
were protected from degradation by quick freezing at -20 οC once collected. 
Thereafter, samples were aliquoted and kept at -80 οC once centrifuged for 5 
- 8 months until used. Also, freezing thaw of the samples, which may lead to 
protein denaturation was avoided during the ELISA procedure.  
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3.7.2 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA is an immunological method.  It is used for detection and quantification 
of proteins, hormones, peptides, and antibodies. Usually 96-well polystyrene 
plates coated by a special antibody or antigen are used in the assay. There 
are several types of ELISA-assay (Figure 5): 
Direct ELISA, indirect ELISA, and sandwich ELISA 
In this study, a Sandwich ELISA was employed. This type of ELISA detects 
the antigen between two layers of antibodies. The wells of the plate are 
coated by capture antibody and blocked, before the sample containing 
antigen is added. An enzyme-linked secondary antibody is added, followed 
by a substrate which reacts with the enzyme bound to the secondary 
antibody to give a color or fluorescent signal that can be measured to 
determine the presence of the antigen. 
 
 
Figure 5: Diagram shows the different types of ELISA (Thermofisher.com). 
 
3.7.2.1 ELISA Procedure  
  
Previous studies in both humans and guineas pigs have used a Human 
Syndecan-1/CD138 ELISA Kit (Diaclone, France) (Rehm et al. 2007). 
However, this company also provides a Murine Syndecan-1/CD138 ELISA 
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Set. When the experiments of the study were designed, it was unclear which 
of the available ELISA kits would optimally detect syndecan-1 in our model. 
Therefore, both ELISA kits (Human Syndecan-1/CD138 ELISA Kit, Cat. No. 
950.640.192, Diaclone, France) and (Murine Syndecan-1/CD138 ELISA Set, 
Cat. No. 861.060.005, Diaclone, France) were used and the results 
compared.  
Both ELISA tests done in this study were based on the sandwich principle, 
using solid-phase monoclonal B-B4 antibody and a biotinylated monoclonal 
B-D 30 antibody raised against syndecan-1. The detection steps rely on 
streptavidin-horseradish peroxidase (HRP), and tetramethylbenzidine (TMB) 
as chromogen. The protein levels were quantified by spectrophotometer 
(SpectraMax plus 384 Microplate Reader, USA) at 450 nm as the primary 
wavelength and 620 nm as the reference wavelength. ELISA procedures and 
assay preparation were carried out in accordance with the supplier’s 
instructions (Diaclone research, Besancon, France). The standard 
concentration ranges of the human antibody kit were from 8 to 256 ng/ml, the 
sensitivity was 4.94 ng/ml and the coefficient of variation in 6 replicates was 
6.2% intra-assay, and 10.2% inter-assay. However, for the murine antibody 
the concentration ranges were from 0.5 to 16 ng/ml, the sensitivity was 0.35 
ng/ml and the specificity was <3.7% with recombinant human CD138.   
3.7.2.2 Murine Syndecan-1/ CD138 ELISA Set  
Since the syndecan-1 in the rat and mouse have greater homology (92.3%) 
than the rat and human (80.5%) (Appendix 7), the murine syndecan-1 
antibody was tried first. Microtiter plates of 96-well were used. The plates 
were coated with 100 µL of diluted capture antibody and incubated overnight 
at 4 οC. After incubation, the plate was washed twice with phosphate-
buffered saline (PBS) containing 0.05% Tween-20 to remove unwanted 
materials. A blocking buffer (250 µL), PBS containing 5% bovine serum 
albumin (BSA) was added to the plate to block non-specific binding sites on 
the surface. After 2 hours incubation at room temperature (18 to 25 οC) on 
the shaker, the plate was again washed three times with PBS. Then 50 µl of 
each sample, standard and zero or blank (standard diluent) were added to 
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the plate in duplicate. Diluted biotinylated detection antibody (50 µl) was 
added to each well and the plate was covered and incubated for 2 hours at 
room temperature on the shaker. Any unbound antibody was removed by 
washing the plate twice. The streptavidin-HRP solution (100 µl) was added to 
every well and after incubation of 30 minutes at room temperature on the 
shaker, the plate was washed two times. A chromogen substrate TMB (100 
µl) was then added to the wells and incubated in the dark by wrapping the 
plate in aluminium foil for 15 minutes at room temperature. TMB reacts with 
HRP to produce a blue color. This reaction is stopped by the addition 100 µl 
of 1 M sulfuric acid, which also turns the color yellow. The amount of color 
produced, as measured using a spectrophotometer (SpectraMax plus 384 
Microplate Reader, USA) was directly proportional to the amount of 
syndecan-1 in the samples and standards (Appendix 6). A standard curve 
was created by plotting the absorbance of each standard against the known 
concentration of each standard (Appendix 6.2.6). This curve was used to 
quantify the syndecan-1 concentration in the samples. Graph Pad Prism 
statistical software was used to conduct the analysis (GraphPad Prism, 
USA). 
3.7.2.3 Human Syndecan-1/CD138 Kit  
   
Each sample, standard, control and zero (standard diluent) (50 µL) were 
added to precoated 96-well microtiter plates in duplicate. The remainder of 
the procedure was identical to that for the Murine ELISA described above 
(Appendix 6.2.7 standard curve). 
Immunohistochemically investigation also was added to determining relative 
syndecan-1 staining intensity between groups (see sections 3.8 and 3.8.1). 
3.8 Histological Investigation 
An additional 12 rats (3 rats per group) were used for histological studies. 
Hearts were isolated and perfused with K-H buffer in a Langendorff system 
as described previously in section 3.3.1, and divided into four groups 
according to the treatment protocol as described in section 3.3.3. At the end 
of the perfusion protocol the hearts were perfusion-fixed immediately 
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thereafter with 4% paraformaldehyde (PFA) in PBS (pH 7.4) at room 
temperature. Fixative was administered using an infusion pump (Graseby 
2100, Medical Smith, UK) by switching off three-way tap (stopcock) to stop 
perfusion of K-H and start infusion of the fixative. Perfusion-fixation were 
continued for 10 minutes in a fume hood after separating the cannulated 
heart together with the stopcock and perfusion fixative line from the main rig 
to avoid contamination of the rig with PFA (Figure 6). The flow rate of fixative 
was set at the same rate as the coronary flow at the end of reperfusion for 
each heart and ranged between 0.5 - 2 ml/min. Hearts were decannulated 
and cut into four pieces similar to that used for TTC assay (see section 3.5), 
and further immersion-fixed in the above fixative solution overnight at 4 ºC, 
and processed to wax using an automatic tissue processor (Leica TP1020, 
Leica Biosystems, Germany). Briefly, tissues were dehydrated in increasing 
concentrations of ethanol, cleared in xylene, impregnated and embedded in 
paraffin wax (Appendix 8.1). Sections were cut using a rotary microtome 
(Leica RM2125RT, Leica Biosystems, Germany) and prepared for 
immunohistochemistry to assess syndecan-1 levels in blood vessels and for 
Haematoxylin and Eosin staining (H&E stain) to assess extracellular edema. 
 
Figure 6: Perfusion-fixation of isolated heart. PFA in the syringe was infused 
at rate ranges between 0.5 - 2 ml/min using an infusion pump connected via 












50 ml syringe 
contains PFA 
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3.8.1 Immunohistochemistry Protocol 
 
3.8.1.1 Preparation of the Sections 
      
Sections of 6 µm thickness (3 sections/heart) were cut and first floated onto 
30% alcohol in water before being transferred to a hot water bath at 43 ºC to 
flatten the section, and then mounted on coated microscope glass slides 
(SuperFrost Plus slides, Thermo Scientific, USA). The slides were stored 
overnight in an oven at 60 ºC. The sections were deparaffinized in xylene, 
rehydrated and rinsed in running tap water (Appendix 8.2.1 and 8.2.2). 
 
3.8.1.2 Immunostaining Procedure 
 
Optimization for immunofluorescent staining was first attempted using mouse 
monoclonal antisyndecan-1 (B-A38, ab 34164, Abcam) on sections from a 
control heart and spleen (PFA-fixed/Paraffin embedded sections) where 
syndecan-1 was expected to be present. The spleen was used as positive 
control as recommended by manufacturers. Some sections were subjected to 
antigen heat retrieval in citrate buffer pH 6 for 5 minutes, followed by the 
staining protocol for syndecan-1. Briefly, after washing in PBS, the sections 
were incubated in 50 mM ammonium chloride in PBS for 30 minutes to 
quench aldehyde-induced auto-fluorescence, and reduce background 
staining when using fluorescent detection. Non-specific binding was blocked 
with 3% BSA in PBS/ 0.1% Triton X-100 for 2 hours at room temperature. 
Thereafter, sections were incubated in increasing dilutions of mouse 
antisyndecan-1 antibody (1:50, 1:100, 1:250, 1:500) overnight at 4 οC in a 
humidity chamber. 
After washing in PBS/ 0.1% Tween-20, sections were incubated with anti-
mouse CY3 secondary antibody 1:1000 dilution (CY3 anti-mouse, Code. No. 
715-166-151, Jackson ImmunoReseatch) for 2 hours in dark humidity 
chamber at room temperature. Sections were mounted with glycerol and 
coverslips were applied. Sections were kept in dark cupboard for better 
viewing on the next day using a fluorescence microscope (Zeiss Axiovert 200 
M fluorescent microscope, Carl Zeiss, Germany) using excitation and 
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emission wavelengths of 546 and 590 nm respectively. However, no 
fluorescence staining was detected in any sections.  
The immunostaining was repeated to increase sensitivity of detection by 
increasing the time of heat antigen retrieval in citrate buffer pH 6 for 20 
minutes, and still no signal was detected.  
Furthermore, the immunofluorescent staining was tried on frozen sections 
which were fixed in 100% methanol to exclude the possibility that the PFA 
fixation and tissue processing procedure might have affected the signal. 
Again, no signal was detected. 
Chromogenic detection was also tried because it is more sensitive than 
immunofluorescent. Briefly, sections were treated with heat antigen retrieval 
in the above buffer or Tris-EDTA pH 9 for 5 minutes. Then endogenous 
peroxidase was blocked with 3% hydrogen peroxide in distilled water to 
reduce background staining of non-specific binding. After BSA blocking of 
non-specific binding sections were incubated with primary antibody (1:50 
dilution) overnight at 4 οC in a humidity chamber. Thereafter, sections were 
incubated with secondary antibody EnVision+ System- HRP Labelled anti-
mouse secondary antibody (K-4000, Dako) for 1 hour at room temperature. 
After washing in PBS/Tween-20, sections were incubated in 3,3-
diaminobenzidine (DAB) (K3467, Dako) and the reaction was observed under 
the light microscope up to 15 minutes to determine at what time point can 
stop the reaction. Again, no signal was detected. 
Since none of the above approaches yielded success, there was strong 
possibility that the antibody was defective. Therefore, immunostaining was 
repeated using a newly purchased rabbit monoclonal [EPR6454] syndecan-1 
antibody (ab216458, Abcam). 
The above immunofluorescent staining protocol without antigen retrieval was 
followed using new antibody (rabbit monoclonal antisyndecan-1 antibody). 
The secondary antibody used for detection was anti-rabbit CY3 secondary 
antibody (CY3 anti-rabbit, Code. No. 711-166-152, Jackson 
ImmunoResearch) using a dilution of 1:2000. Sections were mounted and 
viewed as above (Appendix 8.3.1.1).  
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Furthermore, chromogenic detection also was tried. Whereas half of sections 
were treated for heat antigen retrieval using citrate buffer for 5 minutes. The 
secondary antibody used was goat anti-rabbit HRP- linked (ab6721, Abcam) 
using a dilution of 1:250 for 1 hour at room temperature. Thereafter sections 
were incubated with Vector DAB substrate (DAB Peroxidase kit, Cat.No.SK-
4100, Vector, Burlingame, CA). The DAB reaction was also optimized by 
observation of staining reaction under the light microscope, and the reaction 
was stopped after 5, 6, and 12 minutes by rinsing sections with double 
distilled. After staining, slides were dehydrated and cleared in xylene. 
Coverslips were applied to sections and mounted with Dibutyl phthalate-DPX 
(Sigma). Negative controls were performed by excluding the primary antibody 
only or excluding both antibodies to determine any non-specific cross 
reactivity with secondary antibody or endogenous peroxidase respectively.   
Based on the findings of the above variations in the protocols, the optimal 
conditions for detection of syndecan-1 were found to be a 1:500 dilution of 
primary antibody without antigen retrieval and a 1:250 dilution of HRP-linked 
secondary antibody. The optimal incubation time of section with DAB 
substrate was 6 min. Therefore, the immunostaining protocol for syndecan-1 
on remaining hearts from different experiments and controls was continued 
using these conditions (Appendix 8.3.1.2). 
Tile scan of the entire sections were captured using the Virtual Slide 
Microscope System at 40X objective lens magnification (VS120-L100-W, 
Olympus, Japan). This scan allowed visualizing the entire section and outline 
the ventricle to assess blood vessels which was not possible to do by 
fluorescent microscopy (see image analysis for details). 
3.8.1.3 Image Analysis 
  
A scoring system was used to evaluate the presence of syndecan-1 in blood 
vessels based on a previous study (Kliment and Oury 2012) with a 
modification from their scoring system of 0 - 2 to that of 0 - 3 for this study. 
The left ventricular area in the section was identified on the tile-scanned 
images and 20 vessels (arteries and veins excluding small capillary) of the 
ventricle were visually scored at 40X objective lens magnification. Vessels 
CHAPTER THREE                                           MATERIALS AND METHODS 
47 
 
were scored as 0 = no staining, 1 = mild staining, 2 = moderate staining, 3 = 
intense staining according to their staining intensity (Figure 7). Scoring was 
performed on 3 sections/heart and 3 hearts/group. Scoring data was 
analysed by Non-parametric one-way ANOVA and data presented as score 
mean ± SEM (see the statistical analysis section for data analysis details).  
 
Figure 7: Representative syndecan-1 immunostaining pattern of coronary 
blood vessels. Scoring categories according to staining intensity of the vessel 
wall are shown as described in image analysis section; (A) Score 0 = no 
staining, (B) Score 1 = mild staining, (C) Score 2 = moderate staining, (D) 
Score 3 = intense staining. 
3.8.2 Hematoxylin and Eosin Staining Protocol 
 
3.8.2.1 Preparation and Staining of the Sections 
 
The paraffin-embedded samples of the left ventricle were sectioned to 5 µm 
thickness (3 section/heart), mounted on non-coated microscopic slide 
(Frosted microscope slides, Lasec, SA) and prepared for H&E staining for 
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histological investigation (Appendix 8.3.2). Sections were visualized using an 
upright light microscope at 20X objective lens magnification (Zeiss Axioskop 
2 Mot plus light microscope, Carl Zeiss, Germany) and photographed using 
CCD camera AxioCamHR controlled by Axiovesion 4.7 software (Carl Zeiss, 
Germany). 
3.8.2.2 Image Analysis 
Images of different areas of the left ventricle of each section (3 sections/ 
heart and 3 images/section) were taken (Figure 8). The extracellular 
compartment (i.e. any space outside the cardiomyocytes) of the left 
ventricular field was measured by thresholding this compartment using 
ImageJ software (ImageJ, NIH Image), and was expressed as percentage of 
total area of the field of the image (Figure 9) (Appendix 9 for ImageJ 
analysis).  
 
Figure 8: Shown left ventricular section (PFA/Paraffin embedded) stained 
with Hematoxylin and Eosin stain. Areas 1, 2, 3 represent the site of the 
images captured by the camera system on the light microscope using a 20X 
objective lens as described in image analysis section. 




Figure 9: ImageJ analysis to quantify extracellular compartment. (A) H&E 
stained section of left ventricle using a 20X objective lens. (B) the same 
image as in (A) after thresholding (red) in ImageJ software.  
     
3.9 Statistical Analysis 
In this study, all data were presented as the mean ± SEM. Comparisons 
between multiple groups were performed using one-way ANOVA, and 
repeated measures ANOVA were used for measurements in a single group 
measured more than one time. Non-parametric tests were performed on data 
that were not normally distributed. Post-hoc tests were performed using 
Tukey's test. Vasculature syndecan-1 scoring data was analyzed by non-
parametric ANOVA, Kruskal-Wallis test with a Dunn’s post-test. A value of 
P<0.05 was considered to be statistically significant. GraphPad Prism 
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CHAPTER 4: RESULTS 
 
4.1 Effect of S1P on Infarct Size 
 
Isolated rat hearts subjected to 20 minutes global ischemia and 60 minutes 
reperfusion had an infarct size of 32.34 ± 4.08% of the total ventricular area 
(Figure 10). By comparison, control hearts had significantly lower infarct 
sizes of 17.33 ± 1.59% (P= 0.04, control vs. I/R) and S1P perfused hearts 
had an infarct size of 16.06 ± 4.07 (P=0.02, S1P vs. I/R). Treatment with S1P 
before ischemia (I/R+S1P) significantly decreased infarct size to 14.17± 
4.35% (P= 0.01, I/R+S1P vs. I/R), and there were no significant differences 
(n.s, P>0.05) between the control and the S1P perfused groups.  
 
 
Figure 10: Effect of S1P on infarct size of isolated hearts subjected to 20 
minutes ischemia and 1 h reperfusion. (A) Images of ventricular myocardium 
cross-sections stained with TTC in all four groups. (B) Summary data of 
infarct size. Infarct size is expressed as a percentage of total ventricular area 
(*P<0.05 vs. I/R. N≥6/ group). 
 
 




4.2 Effect of S1P on Hemodynamic Parameters in Isolated 
Perfused Hearts 
The hemodynamic data of the isolated hearts subjected to 20 minutes 
ischemia and 60 minutes reperfusion, with or without S1P treatment, were 
recorded at different time points during the protocol for all groups (Figure 11). 
At the end of the protocol, control hearts had post perfusion LVDP of 40.66 ± 
2.02 mmHg and LVEDP of 26.15 ± 3.82 mmHg. I/R caused a significant 
decrease in LVDP 18.19 ± 4.78 mmHg, (P=0.02 vs. control) and an increase 
LVEDP of 61.37 ± 5.32 mmHg (P<0.0001 vs. control). S1P treatment before 
ischemia did not improve recovery of LVDP (15.51 ± 2.06 mmHg vs. I/R, 
P>0.05 n.s) or LVEDP (69.49 ± 3.62 mmHg vs. I/R, P>0.05 n.s). In S1P 
treated hearts that were not subjected to ischemia, LVDP and LVEDP were 
not significantly different from the control (LVDP: 39.83 ± 4.24 mmHg P=0.99 
vs. control; LVEDP: 12.98 ± 1.86 mmHg, P=0.1 vs. control). HR, CF, NFR, 
and RPP were not significantly different between the groups at the end of 
reperfusion. 
The baseline hemodynamic parameters measured at the end of 20 minutes 
stabilization were not significantly different between the groups. In each 
single group, there was a significant decrease in LVDP and CF by the end of 
reperfusion compared to the values measured at the end of stabilization 
(P<0.0001 at the end vs. baseline). All groups except the S1P perfusion 
group showed a significant increase in LVEDP by the end of reperfusion, 
compared to the baseline values (P<0.001). HR was not significantly different 
at the end of perfusion in comparison to the baseline values in each group 
(P>0.05). All groups, except the S1P treated group with or without ischemia 
(I/R+S1P, S1P perfusion) demonstrated a significant increased NFR by the 
end of reperfusion compared to baseline (P<0.05). Also, the ischemic groups 
(I/R, I/R+S1P) had a significant difference in NFR early after reperfusion, 
compared to the S1P perfusion group (P≤0.002).  
 




Figure 11: Effect of S1P on hemodynamic parameters of isolated hearts for 
all groups. Graphs A-E show the changes in: (A) Left ventricular developed 
pressure (LVDP), (B) Left ventricular end diastoilic pressure (LVEDP), (C) 
Heart rate (HR), (D) Coronary flow (CF), (E) Net filtration rate (NFR) over 
time in each group and (F) Shows rate pressure product (RPP) for each 
group calculated after 60 minutes reperfusion and expressed as percentage 
of the baseline. Control group ( ),  Ischemia/reperfusion group( I/R ), 
Ischemia/reperfusion +S1P (I/R+S1P ), S1P perfusion ( ).* P<0.05, 
**P<0.01 vs. control. +P<0.05, ++P<0.01 vs. S1P perfusion. &P<0.05 I/R vs. 
I/R+S1P. (N≥6/group).  
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4.3 Effect of S1P on Cardiac Edema in the Isolated Perfused 
Heart 
Mean wet-to-dry weight ratios of isolated hearts were measured after 20 
minutes ischemia (or equivalent perfusion for control groups) and 30 minutes 
reperfusion with or without S1P treatment (Figure 12). The ratio was not 
significantly different between the groups (P>0.05). There was also no 
significant difference between the control and K-H groups which were added 
to assess the effect of DMSO on cardiac edema.  
 
Figure 12: Effect of S1P on heart weight wet/dry ratio of isolated hearts 
subjected to 20 minutes ischemia 30 minutes reperfusion (P=n.s, N 
=7/group). 
 
4.4 Effect of S1P Treatment on Syndecan-1 Shedding 
Shedding of the glycocalyx was assessed by measuring the level of 
syndecan-1 in the coronary effluent using ELISA. The results obtained from 
the murine antibody showed no significant differences in the level of 
syndecan-1 between the groups (see Appendix 4.2.7). 
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Using the ELISA with the human antibody, we found that syndecan-1 levels 
in the coronary effluent of the hearts subjected to 20 minutes global ischemia 
followed by reperfusion was 10.22 ± 1.39 ng/ml, which was significantly 
higher than that detected in the control group 3.92 ± 0.76 ng/ml (P=0.0002 
vs. control). Pretreatment with S1P before ischemia did not affect the 
shedding of syndecan-1 which was 8.59 ± 1.14 ng/ml in this group, (P=0.01 
vs. control, P=0.7 vs. I/R). The group treated with S1P without ischemia had 
similar syndecan-1 levels of the control group (3.24 ± 0.47 ng/ml, P=n.s vs. 
control) and was significantly different from the ischemic groups (P<0.0001 
vs. I/R, P=0.0056 vs. I/R+S1P). The level of syndecan-1 in K-H perfusion 
without ischemia was, 2.44 ± 0.57 ng/ml, and was similar values to the 
control (P=n.s vs. control, vs. S1P perfusion, P<0.05 vs. I/R, vs. I/R+S1P) 
(Figure 13).  
 
Figure 13: Quantitative measurement of syndecan-1 release in the coronary 
effluent of isolated hearts. *P< 0.05, ***P<0.001 vs. control, ##P< 0.01, 
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4.5 Immunohistochemistry Assessment of Syndecan-1  
 
4.5.1 Optimization of Immunostaining 
Immunostaining to assess the presence of syndecan-1 in blood vessels using 
mouse monoclonal antisyndecan-1 (B-A38, ab 34164, Abcam) antibody was 
unsuccessful for all protocols used as was evidenced by the absence of 
fluorescence signals. On the other hand, syndecan-1 was detected using 
rabbit monoclonal anti-syndecan-1 antibody. There was positive 
immunofluorescent staining detected in both control heart and splenic 
sections even without antigen retrieval. The negative control where the 
primary antibody was omitted revealed no signal (Figure 14). The staining 
was clear and intense with no significant difference noted between the four 
dilutions of primary antibody used (Figure 15). Therefore, 1:500 dilution of the 
antibody was used for the rest of the experiment.  
 
Figure 14: Immunofluorescent staining of the vessel wall of both heart and 
spleen sections. PFA-fixed/Paraffin-embedded sections were stained for 
syndecan-1 using rabbit monoclonal antisyndecan-1. Positive 
immunofluorescent staining was detected in both sections (left side).  
Syndecan-1 signals were not detected in the negative controls of both 
sections where the primary antibody was omitted (right side).  




Figure 15: Immunofluorescent staining of coronary vessels (arrow site) of 
heart tissue (PFA-fixed/Paraffin embedded sections) with four different 
dilutions of primary antibody of rabbit monoclonal antibody against syndecan-
1. There was clear positive staining in all sections with no significant 
difference in fluorescence intensity between four dilutions.  
 
4.5.2 Assessment of Syndecan-1 by Chromogenic Immunostaining 
  
Chromogenic staining of cardiac sections (PFA-fixed/Paraffin embedded 
sections) was used for assessment of the presence of syndecan-1 in blood 
vessels using the antirabbit antisyndecan-1 antibody. This method was 
preferred as tile-scanned images could be produced which was not possible 
for fluorescent-stained sections. Generally, the staining intensity of the 
ventricular sections of non-ischemic groups (control and S1P) was very 
intense in comparison to that of the ischemic groups (I/R and I/R+S1P), and 
the staining was more intense in the area close to the epicardial and 
endocardial regions (Figure 16).  
 
 




Figure 16: Chromogenic staining of left ventricular sections (PFA-
fixed/Paraffin-embedded) stained with rabbit monoclonal antibody against 
syndecan-1. Staining intensity was more intense in non-ischemic hearts 
(control and S1P) than in ischemic hearts (I/R and I/R+S1P) and the staining 
was more intense in the area close to epicardium and endocardium regions 
(arrow site). Paraformaldehyde (PFA), ischemia/reperfusion (I/R), 
sphingosine-1-phosphate (S1P).   
Syndecan-1 staining level of blood vessels was scored according to the 
staining intensity. The intensity of syndecan-1 staining was significantly 
decreased or absent in ischemic group (0.66 ± 0.04) in comparison to the 
control group (2.56 ± 0.03, P≤ 0.001 I/R vs. control) and the staining reaction 
was found in both the endothelial lining and medial layer of blood vessels. 
Treatment with S1P before ischemia (I/R+S1P) had no effect on syndecan-1 
intensity compared to the I/R group (0.56 ± 0.03, P=n.s I/R+S1P vs. I/R). 
Syndecan-1 intensity in hearts treated with S1P without ischemia (S1P) was 
not significantly different to control hearts but was significantly higher in 
groups that underwent ischaemia with and without pre S1P treatment (2.38 ± 
0.04, P<0.001 vs. I/R, vs. I/R+S1P, P= n.s vs. control) (Figure 17 A, B). 
Endocardium Epicardium 
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(Appendix 10 a table summarizes the statistical data of syndecan-1 staining 

















Figure 17: Syndecan-1 immunostaining of the coronary vessels in PFA/ 
Paraffin-embedded sections of the left ventricle of the isolate rat heart. (A) 
Histological scoring of syndecan-1 staining of the left ventricular vasculature. 
Data are reported as mean score ± SEM. ***P<0.001 vs. control, ###P<0.001 
vs. S1P perfusion group. (B) Representative images of syndecan-1 staining. 
Control and S1P Perfusion hearts show an intense staining of vessel wall, 
whereas no staining is seen after I/R. Minimal/mild staining can be observed 
after treatment with S1P before I/R (I/R+S1P).    
(A) 
(B) 
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4.5.2 Cardiac Morphological Features and Quantification of Cardiac 
Edema 
 
The morphological examination of cardiac cells in H&E-stained left ventricular 
sections revealed that myocardial fibres of control and S1P treated hearts 
were regularly arranged with clear striations, intact cell membrane and there 
were small spaces between the fibres. Hearts that were subjected to I/R 
displayed some ischemic features such as shortening of muscle fibres, 
swelling of the cells and ruptured cell membranes with loss of striation and 
increased separation of the muscle fibres. Hearts that were treated with S1P 
before ischemia also displayed some ischemic changes (Figure 18. A).  
The ratio of interstitial area (i.e. excluding cardiomyocytes) to the total area of 
the image field was measured to quantify cardiac edema. In the control 
hearts, interstitial area was 37.06 ± 0.95% and significantly increased in the 
ischemic group (43.48 ± 1.07%, P≤0.001 control vs. I/R). Treatment with S1P 
before ischemia significantly decreased interstitial area to control levels 
(37.43 ± 0.96%, P≤0.01 I/R+S1P vs. I/R, P>0.05 I/R+S1P vs. control). S1P 
treatment without ischemia had no effect on interstitial area (37.96 ± 1.53%, 
P=n.s S1P vs control and S1P+I/R) (Figure 18. B).  (Appendix 11 a table 








































Figure 18: Quantification of cardiac edema in H&E-stained wax sections of 
the left ventricle. (A) Morphological features of cardiac tissue in four groups.  
(B) Extracellular area as percentage of total area.  ***P≤0.001 vs. control, 
**P≤0.01 vs. I/R+S1P vs S1P perfusion group.  
(B) 
(A) 
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CHAPTER 5: DISCUSSION 
 
This study aimed to explore whether the known cardioprotective effect of S1P 
in isolated rat heart during I/R injury was mediated via the stabilization of the 
endothelial glycocalyx. The results showed that S1P treatment of the isolated 
rat heart subjected to I/R injury led to a significant decrease in infarct size, 
and extracellular edema without an effect on the functional recovery of the 
heart, NFR and wet/dry heart weight ratio. However, S1P had no effect on 
the increased level of syndecan-1 in the coronary effluent caused by I/R 
injury. In addition, histological assessment of syndecan-1 shedding in 
coronary vessels revealed complete shedding of syndecan-1 as result of I/R 
damage and pretreatment with S1P had no effect. 
In the current study, S1P protected the heart against I/R injury, as was 
demonstrated by a decrease in infarct size. However, there was no 
accompanying change in hemodynamic recovery.  The effect of S1P on the 
infarct size in this study was consistent with other studies which used the 
same dose of S1P (Kelly-Laubscher et al. 2014). Therefore, 10 nM of S1P 
was effective in reducing the infarction without effect on the hemodynamic 
function. These results are similar to some other studies that also reported 
decreases in infarct size without changes in the functional recovery when 
various drugs were tested (Kelly-Laubscher et al. 2014; Alizadeh et al. 2011). 
A possible explanation is that although S1P can reduce the infarct size, it 
may not improve post reperfusion cardiac dysfunction because the 
myocardium may be reversibly stunned and require more time to improve. 
Myocardial stunning is defined as post-ischemic ventricular dysfunction and 
occurs after ischemia and persists even after reperfusion (Takano et al. 
2000). Another possibility is that the onset of action of S1P to improve 
functional parameters is different from the time of the injury occurrence that is 
suggested to occur within 5 minutes after reperfusion. In addition, one study 
used a higher dose of S1P (1 and 10 mM) and they found improvement in the 
LVDP and decreased infarct size (Tsukada et al. 2007). Therefore, although 
10 nM S1P has been used in many studies and was determined to decrease 
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infarct size (Kelly-Laubscher et al. 2014; Lecour et al. 2002; Somers et al. 
2012) greater concentrations may be needed to improve cardiac 
hemodynamics. However, higher concentrations of S1P may lead to side-
effects of S1P such as bradycardia, coronary vasoconstriction, and 
decreased blood pressure (Murakami et al. 2010; Sugiyama et al 2000). 
The filtering capacity of the endothelial barrier was determined by measuring 
the NFR, and heart wet/dry weight ratio. NFR was significantly increased 
after 5 minutes reperfusion in ischemic groups (I/R, and I/R+S1P) in 
comparison to the S1P perfusion group (p=0027 vs. S1P), with no significant 
differences at the end of reperfusion between the groups. The increase in the 
NFR shortly after reperfusion in the ischemic groups may indicate an 
increase in endothelial permeability. However, similar differences in NFR 
were not seen between the ischemic groups and the control group, and may 
be due to a trend in the S1P-treated hearts to have a lower NFR. This result 
is similar to a study that tested the effect of S1P on intact vessels which 
found that S1P maintains normal vascular permeability by maintaining the 
endothelial barrier in intact microvessels (Zhang et al. 2016). Furthermore, 
another study by Zeng et al. (2014) found that S1P can stabilize the 
glycocalyx in cultured rat fat-pad endothelial cells in presence of plasma 
albumin, and the S1P dose used in this study was higher than used in this 
study.  
There was no significant difference in heart weight wet/dry ratio as an 
indication of cardiac edema between control and ischemic hearts. 
Theoretically, this could have been attributed to an effect by the vehicle 
DMSO on the fluid permeability in the control group. However, this possibility 
was excluded when an additional group perfused with K-H alone was 
studied. The level of edema for the K-H group was not significantly different 
from control hearts which received DMSO. S1P had no effect on heart 
wet/dry ratio after ischemia, but the S1P perfusion group demonstrated a 
trend of decreased heart wet/dry ratio, which is consistent with the NFR 
results. 
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Histological assessment of cardiac edema was determined by measuring the 
extracellular area. The extracellular area was increased by ischemia and this, 
may indicate increased extracellular edema. S1P pretreatment led to 
decreased extracellular area which may indicate that S1P decreased cardiac 
edema. These histological results were not consistent with the heart weight 
wet/dry ratio measurements, which may be surprising as they are both 
measures of edema. The difference in these results may be related to the 
method itself. Some studies have suggested that histological assessment is 
more specific and can distinguish between extracellular and intracellular 
edema with excluding intravascular water residue which cannot be excluded 
using heart weight wet/dry ratio (Fehrenbach et al. 2001; Fehrenbach et al. 
1999).  Moreover, fixation of the tissue sample by an appropriate procedure 
can give adequate preservation of the fluid accumulation. However, in this 
study only extracellular edema was measured. The intracellular edema was 
not clear to measure. There are two possible reasons for this; Firstly, the 
cells may not have been sufficiently damaged, due to the short ischemic 
duration used in this study, to cause increased intracellular edema. Secondly, 
there is a possibility that intracellular edema resolved after reperfusion. This 
has been indicated by other studies which showed that intracellular edema is 
an ischemic event and resolved after reperfusion (Askenasy et al. 1995; 
Askenasy and Navon, 1997; Askenasy and Navon, 2005; Fernandez-
Jimenez et al., 2015). 
Previously,  Straus (2013) indicated from their histological assessment of 
myocardial edema after I/R, that S1P may act to decrease post-ischemic 
myocardial edema. Their study obtained a non-significant trend of edema 
formation in the ischemic group and S1P pretreatment seemed to improve 
the cardiac edema to levels close to that of the control, but there were no 
significant differences between the groups, and this supports my results.  
The results of this study show that I/R increased the release of syndecan-1 in 
the coronary effluent, and this may indicate glycocalyx damage. This result 
was consistent with other studies which  also demonstrated that I/R caused 
damage to the glycocalyx, and leads to release of its components in the 
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coronary effluent (Rehm et al. 2007; Chappell et al. 2011; Mulivor and 
Lipowsky 2004). These findings are also consistent with the NFR results 
described above and may suggest increased endothelial permeability at 5 
minutes of reperfusion. In this study, treatment with S1P before ischemia had 
no effect on syndecan-1 release and suggests that S1P may not protect the 
heart via stabilization of the glycocalyx. However, this study focused on the 
most commonly assayed glycocalyx by-product syndecan-1. It is possible 
that S1P protects via other components of glycocalyx, such as heparan 
sulphate and hyaluronic acid. Several other studies testing the protective 
effect of drugs on the glycocalyx have measured two or more components of 
glycocalyx (Chappell et al. 2009a; Zeng et al. 2014), because some drugs 
can stabilize one component without any effect on the others. It is also 
possible that the concentration used in the current study was too low to 
protect the glycocalyx. Zeng et al. (2014) found the protective level of S1P in 
cultured rat fat-pad endothelial cells ranged from 0.2 µM to 1 µM even when 
there is no protein carrier for S1P, which is above the concentration used in 
this study. In any case, the results of this study indicate that S1P, at a 
concentration that decreased infarct size, did not significantly decrease the 
elevated level of syndecan-1 in coronary effluent in ischemic hearts 
suggesting that this cardioprotective dose of S1P had no effect on the 
syndecan-1 shedding. To strengthen this argument, a power analysis was 
conducted and revealed that the number of rats used in ELISA was sufficient 
to give 80% power to detect differences between means with a significance 
level of 0.05. In addition, immuno-staining images of syndecan-1 assessment 
in coronary vessels supported the ELISA results revealing decreased 
syndecan-1 after I/R, and similar decreases in syndecan-1 staining in 
ischemic S1P treated hearts.  
In the present study, we evaluated the ability of two different antibodies to 
determine the syndecan-1 level in rat coronary effluent by ELISA. While the 
murine antibodies failed to detect the syndecan-1 in my sample, which was 
assumed to work better since the rat and mouse are more homologous than 
the rat and human (Appendix 7), the human antibody successfully measured 
syndecan-1 in my samples. While it is possible that the murine ELISA failed 
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due to experimental error, such as preparation of the coronary samples, this 
is unlikely since the same samples were used with both antibodies. The 
murine antibody seems to fail to detect the syndecan-1 in our samples 
despite its detection of the standard concentration. Therefore, the specificity 
and the sensitivity of the antibody were most likely the cause of murine 
antibody failure to detect the syndecan-1.  
5.1 Limitations of the Study 
 
Separation of the hearts from the whole animal and Langendorff perfusion 
technique are synthetic procedures that remove the hormonal and neural 
effect on the heart and thus may reduce the clinical relevance of our study. 
The heart is a very delicate and soft tissue and must be handled gently 
during isolation and instrumentation as the heart is susceptible to contusion 
injuries. In addition, isolation of the heart from the whole body will prevent the 
normal humoral and neural regulation of the heart and aortic valve 
incompetence may occur during cannulation, or due to retrograde perfusion 
that prevents the perfusate going from the aorta to the coronary vessels. A 
heart perfused on the Langendorff system may deteriorate in contractile 
function at approximately 5–10% per hour (Skrzypiec-Spring et al. 2007; Bell, 
Mocanu, and Yellon 2011). Furthermore, the K-H buffer, a crystalloid buffer 
used to perfuse the isolated hearts, has restricted capability to give enough 
oxygenation to the tissue which may be associated with deterioration of the 
cardiac function. Also, K-H has low oncotic pressure, compared to blood 
which can cause tissue edema.  
Another limitation of the study is the fact that we pretreated hearts with 
heparin to minimize thrombus formation. There are studies that have shown 
the effect of heparin on the endothelial permeability and shedding of the 
glycocalyx. These studies were inconsistent in their findings, with some 
finding that heparin induced shedding of glycocalyx, and increased 
endothelial permeability (VanTeeffelen et al. 2007) and others finding that 
treatment of a canine septic shock model with heparin restored the 
permeability barrier and protected the glycocalyx against shedding (Yini et al. 
2015).  
 CHAPTER FIVE                                                                                         DISCUSSION 
66 
 
Finally, information from isolated heart studies is difficult to convert into 
clinical use, because most of the experimental studies on cardioprotection 
have been done in young healthy animal models, in contrast to the reality 
that most of the heart disease in humans is accompanied with other systemic 
disorders and pre-existing disease. In future, further studies using a whole 
living animal rather than an isolated heart model may be required to 
investigate the general effects of S1P and allow examining of its long-term 
effects on the cardiac tissues. 
5.2 Future Studies 
To clarify the role of the glycocalyx in S1P-induced cardioprotection, further 
studies should explore the effect of S1P on other components of glycocalyx. 
We could repeat the experiments using different doses of S1P, measuring 
more than one component of glycocalyx using ELISA or other procedures 
such as western blot, immunohistochemistry and electron microscopy.                                                                           
Many studies have shown the effect of global ischemia on the glycocalyx 
shedding, so it is important to explore the effect of regional ischemia on 
shedding of glycocalyx, which is more clinically relevant. This study used 
isolated rat hearts with global ischemia. Since other studies used guinea 
pigs, which are known to have large collateral supply to the heart, to 
investigate the glycocalyx damage our results and protocol may open the 
possibility to test other drugs to protect the glycocalyx in the rat in regional 
ischemia.                                                                        
In order to clarify the effect of the S1P on endothelial barrier integrity and 
cardiac edema, further work may include repeats of histological analysis 
accompanied by some modification in the methods, such as adding albumin 
to K-H perfusate to avoid using crystalloid K-H which has low oncotic 
pressure. In addition, measuring microvascular permeability by using Evan-
blue dyed albumin to quantify colloid protein extravasation could be carried 
out.  
        





This study showed that I/R leads to disturbances in cardiac function, 
increased infarct size, increased release of syndecan-1 in the coronary 
effluent and histological changes. S1P treatment protects the heart against 
I/R injury, as was indicated by the decreased infarct size and decreased 
cardiac edema. However, it had no effect on the shedding of syndecan-1 and 
hemodynamic performance. These results, while confirming the 
cardioprotective effect of S1P, may suggest that this protection is not 
mediated by protection of the glycocalyx via stabilization of syndecan-1. It is 
possible that S1P may protect the glycocalyx by stabilizing other glycocalyx 
components that were not measured in the present study. Although this study 
did not demonstrate a role for the glycocalyx in S1P-induced protection, this 
is the first study that measured syndecan-1 in the cardiac effluent of the 
isolated heart of rats with global ischemia. The study opens up prospects of 
investigating the role of the glycocalyx in other models of I/R injury, including 
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1. Krebs-Henseleit Buffer for Langendorff Perfusion (3 L) 
NaCl 118.5 mM 20.775 g
KCl 4.7 mM 1.051 g
NaHCO3 25 mM 6.301 g
KH2PO4 1.2 mM 0.490 g
Glucose 11 mM 5.945 g
MgSO4 1.2 mM 0.433 g
CaCl2 1.8 mM 0.599 g





2. Preliminary Data: Testing Duration of Ischemia  
 
For optimization of ischemia duration some preliminary experiments were 
done to demonstrate the perfusion protocol conditions and duration. Whereas, 



























25 minutes ischemia 
























































































































































































3. Preliminary data: Comparing Values at the Baseline to the 















Duration of ischemia 20 min 25 min 30 min
Number of hearts 4 3 1
Recovery after ischemia Yes No No
LVDP (mmHg)
Baseline 70.51 ± 8.97 74.63 ± 2.38 116.96 ± 0.0
End of reperfusion 2.27 ± 1.08 0.00 ± 0.0 0.00 ± 0.0
LVEDP (mmHg)
Baseline 8.65 ± 2.2.42 11.89±1.36 7.29 ± 0.0
End of reperfusion 66.73 ± 8.12 0.00 ± 0.0 0.00 ± 0.0
Heart rate (bpm)
Baseline 285.00 ± 15.00 320 ± 20.00 300 ± 0.0
End of reperfusion 225 ± 15.00 0.00 ± 0.0 0.00 ± 0.0
Coronary flow (CF)
Baseline 6.25 ± 1.34 12.83± 3.09 30 ± 0.00





4. Hemodynamic Parameters Measured at the End of 
Stabilization Compared to the Measurements at the End of 
Reperfusion: *P<0.05, vs. control, vs. S1P perfusion. ****P<0.0001, 





Parameters Baseline Reperfusion at 60 min
LVDP (mmHg)
Control 95.9 ± 5.6 40.6 ± 2.0
I/R 93.9 ± 7.2 18.1 ±  4.7 *
I/R+S1P 89.3± 8.4 15.5 ± 2.1 *
S1P Perfusion 88.4 ± 4.7 39.8 ± 4.2
LVEDP (mmHg)
Control 6.4 ± 0.6 26.1± 3.8
I/R 8.4 ± 0.9 61.4 ± 5.3 ****
I/R+S1P 6.5 ± 0.9 69.5 ± 3.6 ****
S1P Perfusion 7.0 ± 0.8 13.1 ± 1.9
Heart rate (bpm)
Control 310  ±  15 220 ± 12
I/R 317 ± 17 257 ± 17
I/R+S1P 360 ± 0 280 ± 25
S1P Perfusion 317 ± 17 218 ± 30
Coronary flow (ml/min)
Control 4.6 ± 0.7  0.6 ± 0.1
I/R 3.7  ± 0.4 0.9 ± 0.1
I/R+S1P 3.5  ± 0.5 0.7  ± 0.1
S1P Perfusion 3.2  ±  0.7 1.3 ±  0.2
Net filtration rate
Control 0.6 ± 0.1 3.1 ±  0.4
I/R 1.0 ± 0.3 2.7 ± 0.3
I/R+S1P 1.7 ± 0.6 3.4 ± 1.0





5. TTC Stain from Defrosted Heart Sections  
 
1. Recipe for TTC buffer solution A  
Monobasic sodium (acidic phosphate)    15.6 g              
Distilled water                                         1000 ml          
2. Recipe for TTC buffer solution B 
100 µM Dibasic sodium (alkaline phosphate)    14.2 g                
Distilled water                                                   1000 ml          
3. Recipe for 1% TTC solution  
Mix 4 parts solution B with 1 part solution A and titrate to pH 7.4, add 250 mg 
TTC in 25 ml buffer solution. 
TTC stain was conducted using the standard protocol 
Infarct size quantification with ImageJ  
File  Open      View one side of the heart at a time
Zoom to accurate viewing  Select polygonal icon  Hold shift and 
click on the outline of heart slide then release shift Select analysis 
icon Measure (this will measure the entire area of all the slices) 
Edit Clear outside  Image     colure  
Split channel   Close the other windows use only the green one
Image Adjust    Threshold. 
The gray area represents the infarct area, with image J this cannot be 
measured so there is a need to measure the red area and minus it from the 
total in an excel worksheet, then the infarct area presented as percentage to 







6. ELISA Preparation and Method 
 
6.1 Preparation of ELISA Solutions 
 
1. 1×Phosphate Buffered Saline (PBS Buffer) Recipe 
a- Dissolve the following in 800 ml distilled water H2O. 
• 8 g of NaCl 
• 0.2 g of KCl 
• 1.44 g of Na2HPO4 
• 0.24 g of KH2PO4 
b- Adjust pH to 7.4 with HCl. 
c- Adjust volume to 1 L with additional distilled water. 
d- Sterilize by autoclaving.  
2. Blocking buffer (1×PBS, 5% BSA) 
 Add 2.5 g bovine serum albumin (BSA) to 50 ml of PBS.  
3. Wash buffer (1×PBS, 0.05% Tween 20) 
Add 45 µL of Tween 20 to 100 ml PBS    
4. Standard and secondary antibody dilution buffer (1×PBS, 1% BSA) 
 Add 0.15 g BSA to 15 ml PBS. 
5. Coating buffer (1×PBS, pH 7.2-7.4) 
 
6. HRP diluent buffer (1×PBS, 1% BSA, 0.1% Tween 20) 
 Add 0.25 g BSA to 25 ml PBS to 22.5 µL Tween 20.  
7. Reconstitution buffer (1×PBS, 0.09% Azide) 
Add 0.09 g Azide to 100 ml PBS 
8. Stop reagent (1 M sulfuric acid) 






6.2 ELISA Assay Preparation 
  
6.2.1 Assay Design 
 
This figure represents the design of organization of samples which are 




6.2.2 Preparation of Standard  
  
Standard vials reconstituted with volume of standard diluent (0.76 ml) this 
gives stock solution of 256 ng/ml of CD138. Serial dilution of the standard is 
made directly in the assay to provide the concentration range from 256 to 8 
ng/ml. A fresh standard curve is produced for every new assay. 
6.2.3 Preparation of Biotinylated Antibody (Anti-CD138) 
 
This antibody is prepared immediately before use. 96-wells plate need to 
dilute 240 µl of biotinylated antibody into 6.36 ml of biotinylated antibody 
diluent. 
6.2.4 Preparation of Streptavidin-HRP 
Dilute the 5 µl vial of streptavidin-HRP with 0.5 ml of HRP diluent immediately 
before use. Then further dilution required according to the number of wells, for 
96-wells need to dilute 150 µl into 10 ml streptavidin-HRP. 
Standards
/Controls Sample wells













6.2.5 Summary of the Method 
 
Add 50 µl of sample and diluted standard /control and 50 µl biotinylated anti 
CD138 
 
Incubate 1 hour at room temperature 
 
Wash three times 
 
Add 100 µl of streptavidin-HRP 
 
Incubate for 30 min 
 
Wash three times 
 
Add 100 µl of ready to use TMB 
 
Protect from light and incubate for 12-15 min 
 
Add 100 µl sulfuric acid 
 










6.2.6 (A) Syndecan-1 Standard Curve, (B) Syndecan-1 levels using 












6.2.7 Syndecan-1 Standard Curve of Human Kit 
 







































7. Syndecan-1 Homology across the Mouse, Rat, Human 
Comparison between the amino acid sequences of syndecan-1 across the 
species (human, rat, mouse) using Pair Wise Sequences Alignment> 
Emboss Needle program  
 
7.1 Syndecan-1 Homology Between Human vs. Rat 
 
######################################## 
# Program: needle 
# Rundate: Mon 30 Jan 2017 11:46:29 
# Commandline: needle 
#    -auto 
#    -stdout 
#    -asequence emboss_needle-I20170130-114628-0077-20079328-
es.asequence 
#    -bsequence emboss_needle-I20170130-114628-0077-20079328-
es.bsequence 
#    -datafile EBLOSUM62 
#    -gapopen 10.0 
#    -gapextend 0.5 
#    -endopen 10.0 
#    -endextend 0.5 
#    -aformat3 pair 
#    -sprotein1 
#    -sprotein2 
# Align_format: pair 





# Aligned_sequences: 2 
# 1: AAH08765.1 
# 2: AAH61834.1 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# 
# Length: 313 
# Identity:     240/313 (76.7%) 
# Similarity:   252/313 (80.5%) 
# Gaps:           3/313 ( 1.0%) 









AAH08765.1         1 
MRRAALWLWLCALALSLQPALPQIVATNLPPEDQDGSGDDSDNFSGSG
AG     50 
                     |||||||||||||||.|||||||||..|:|||||||||||||||||||.| 
AAH61834.1         1 
MRRAALWLWLCALALRLQPALPQIVTANVPPEDQDGSGDDSDNFSGSG
TG     50 
 
AAH08765.1        51 
ALQDITLSQQTPSTWKDTQLLTAIPTSPEPTGLEATAASTSTLPAGEGPK    
100 
                     ||.|:|||:||||||||..||||.||:||||..:..|..||.|||||.|: 
AAH61834.1        51 
ALPDMTLSRQTPSTWKDVWLLTATPTAPEPTSRDTEATLTSILPAGEKPE    
100 
 
AAH08765.1       101 EGEAVVLPEVEPGLTAR--
EQEATPRPRETTQLPTTHQASTTT-ATTAQE    147 
                     |||.|...|.||..|||  |:|||.|||||||||.|.||||.. |||||. 
AAH61834.1       101 
EGEPVAHVEAEPDFTARDKEKEATTRPRETTQLPVTQQASTAARATTAQ
A    150 
 
AAH08765.1       148 
PATSHPHRDMQPGHHETSTPAGPSQADLHTPHTEDGGPSATERAAEDG
AS    197 
                     ..|||||.|:|||.|||..|..|.|.|...|..||||.|..:...||..: 
AAH61834.1       151 
SVTSHPHGDVQPGLHETLAPTAPGQPDHQPPSVEDGGTSVIKEVVEDET
T    200 
 
AAH08765.1       198 
SQLPAAEGSGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGATGASQG
LL    247 
                     :||||.|||||||||||||||||||..||||.|||||||:|||||||||| 
AAH61834.1       201 
NQLPAGEGSGEQDFTFETSGENTAVAGVEPDLRNQSPVDEGATGASQG
LL    250 
 
AAH08765.1       248 
DRKEVLGGVIAVGLVGLIFAVCLVGFMLYRMKKKDEGSYSLEEPKQANG
G    297 
                     |||||||||||.||||||||||||.||||||||||||||||||||||||| 
AAH61834.1       251 
DRKEVLGGVIAGGLVGLIFAVCLVAFMLYRMKKKDEGSYSLEEPKQANG
G    300 
 
AAH08765.1       298 AYQKPTKQEEFYA    310 










7.2 Syndecan-1 Homology Between Human vs. Mouse  
Human vs. mouse######################################## 
# Program: needle 
# Rundate: Mon 30 Jan 2017 12:01:22 
# Commandline: needle 
#    -auto 
#    -stdout 
#    -asequence emboss_needle-I20170130-120121-0691-66201215-
oy.asequence 
#    -bsequence emboss_needle-I20170130-120121-0691-66201215-
oy.bsequence 
#    -datafile EBLOSUM62 
#    -gapopen 10.0 
#    -gapextend 0.5 
#    -endopen 10.0 
#    -endextend 0.5 
#    -aformat3 pair 
#    -sprotein1 
#    -sprotein2 
# Align_format: pair 





# Aligned_sequences: 2 
# 1: AAH08765.1 
# 2: CAA80254.1 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# 
# Length: 312 
# Identity:     237/312 (76.0%) 
# Similarity:   248/312 (79.5%) 
# Gaps:           3/312 ( 1.0%) 





AAH08765.1         1 
MRRAALWLWLCALALSLQPALPQIVATNLPPEDQDGSGDDSDNFSGSG





                     |||||||||||||||.||||||||||.|:|||||||||||||||||||.| 
CAA80254.1         1 
MRRAALWLWLCALALRLQPALPQIVAVNVPPEDQDGSGDDSDNFSGSG
TG     50 
 
AAH08765.1        51 
ALQDITLSQQTPSTWKDTQLLTAIPTSPEPTGLEATAASTSTLPAGEGPK    
100 
                     ||.| |||:||||||||..||||.||:||||......|.||.|||||.|: 
CAA80254.1        51 ALPD-
TLSRQTPSTWKDVWLLTATPTAPEPTSSNTETAFTSVLPAGEKPE     99 
 
AAH08765.1       101 EGEAVVLPEVEPGLTAR--
EQEATPRPRETTQLPTTHQASTTTATTAQEP    148 
                     |||.|:..|.|||.|||  |:|.|.|||||.|||.|.:|||...||||.. 
CAA80254.1       100 
EGEPVLHVEAEPGFTARDKEKEVTTRPRETVQLPITQRASTVRVTTAQAA    
149 
 
AAH08765.1       149 
ATSHPHRDMQPGHHETSTPAGPSQADLHTPHTEDGGPSATERAAEDGA
SS    198 
                     .|||||..||||.||||.|..|.|.|...|..|.||.|..:...|||.:: 
CAA80254.1       150 
VTSHPHGGMQPGLHETSAPTAPGQPDHQPPRVEGGGTSVIKEVVEDGT
AN    199 
 
AAH08765.1       199 
QLPAAEGSGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGATGASQGL
LD    248 
                     ||||.|||||||||||||||||||.||||..|||.|||:|||||||.||| 
CAA80254.1       200 
QLPAGEGSGEQDFTFETSGENTAVAAVEPGLRNQPPVDEGATGASQSL
LD    249 
 
AAH08765.1       249 
RKEVLGGVIAVGLVGLIFAVCLVGFMLYRMKKKDEGSYSLEEPKQANGG
A    298 
                     ||||||||||.||||||||||||.|||||||||||||||||||||||||| 
CAA80254.1       250 
RKEVLGGVIAGGLVGLIFAVCLVAFMLYRMKKKDEGSYSLEEPKQANGG
A    299 
 
AAH08765.1       299 YQKPTKQEEFYA    310 
                     |||||||||||| 









7.3 Syndecan-1 Homology Between Rat vs. Mouse 
######################################## 
# Program: needle 
# Rundate: Mon 30 Jan 2017 12:03:50 
# Commandline: needle 
#    -auto 
#    -stdout 
#    -asequence emboss_needle-I20170130-120349-0345-83427194-
es.asequence 
#    -bsequence emboss_needle-I20170130-120349-0345-83427194-
es.bsequence 
#    -datafile EBLOSUM62 
#    -gapopen 10.0 
#    -gapextend 0.5 
#    -endopen 10.0 
#    -endextend 0.5 
#    -aformat3 pair 
#    -sprotein1 
#    -sprotein2 
# Align_format: pair 





# Aligned_sequences: 2 
# 1: AAH61834.1 
# 2: CAA80254.1 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# 
# Length: 313 
# Identity:     283/313 (90.4%) 
# Similarity:   289/313 (92.3%) 
# Gaps:           2/313 ( 0.6%) 





AAH61834.1         1 
MRRAALWLWLCALALRLQPALPQIVTANVPPEDQDGSGDDSDNFSGSG
TG     50 
                     |||||||||||||||||||||||||..||||||||||||||||||||||| 
CAA80254.1         1 
MRRAALWLWLCALALRLQPALPQIVAVNVPPEDQDGSGDDSDNFSGSG






AAH61834.1        51 
ALPDMTLSRQTPSTWKDVWLLTATPTAPEPTSRDTEATLTSILPAGEKPE    
100 
                     |||| |||||||||||||||||||||||||||.:||...||:|||||||| 
CAA80254.1        51 ALPD-
TLSRQTPSTWKDVWLLTATPTAPEPTSSNTETAFTSVLPAGEKPE     99 
 
AAH61834.1       101 
EGEPVAHVEAEPDFTARDKEKEATTRPRETTQLPVTQQASTAARATTAQ
A    150 
                     |||||.||||||.|||||||||.|||||||.|||:||:||| .|.||||| 
CAA80254.1       100 
EGEPVLHVEAEPGFTARDKEKEVTTRPRETVQLPITQRAST-VRVTTAQA    
148 
 
AAH61834.1       151 
SVTSHPHGDVQPGLHETLAPTAPGQPDHQPPSVEDGGTSVIKEVVEDET
T    200 
                     :|||||||.:|||||||.|||||||||||||.||.||||||||||||.|. 
CAA80254.1       149 
AVTSHPHGGMQPGLHETSAPTAPGQPDHQPPRVEGGGTSVIKEVVEDG
TA    198 
 
AAH61834.1       201 
NQLPAGEGSGEQDFTFETSGENTAVAGVEPDLRNQSPVDEGATGASQG
LL    250 
                     ||||||||||||||||||||||||||.|||.||||.|||||||||||.|| 
CAA80254.1       199 
NQLPAGEGSGEQDFTFETSGENTAVAAVEPGLRNQPPVDEGATGASQS
LL    248 
 
AAH61834.1       251 
DRKEVLGGVIAGGLVGLIFAVCLVAFMLYRMKKKDEGSYSLEEPKQANG
G    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
CAA80254.1       249 
DRKEVLGGVIAGGLVGLIFAVCLVAFMLYRMKKKDEGSYSLEEPKQANG
G    298 
 
AAH61834.1       301 AYQKPTKQEEFYA    313 
                     ||||||||||||| 









8. Histological Protocols  
8.1 Tissue Preparation 
8.1.1 Fixation of the Tissues 
 
Tissue were perfused-fix with 4% PFA in PBS and cut into four pieces, before 
immersion-fix over night at 4 οC in the same buffer. 
-Preparation of 1 L of 4% PFA solution in PBS used for tissue fixation. 
 
- For 1 L PFA solution, add 800 ml of 1 X PBS (pH 7.4) to a glass beaker on a 
stir plate in fume hood. 
- Add 40 g of PFA powder to the PBS. Heat gradually until 60 οC while stirring 
without letting the solution to boil. 
-The PFA powder will gradually dissolve into the solution until the solution 
clears. 
- Let the solution to cool once the PFA dissolved then filtered.  
- Adjust the pH to 7.4. 
- Adjust the volume of the solution to 1 L with PBS and stored at 4 οC. 
8.1.2 Tissue Processing 
 
Once tissues fixed, tissues were processed using a gentle agitation on 
standard tissue processing system (Leica TP1020, Germany) as follow: 
1- Dehydration stage in which the tissues were dehydrated in increasing 
concentration of alcohol: 
• 70% alcohol     2 x 1 hour 
• 96% alcohol      2 x 1 hour 
• 100% alcohol    2 x 1 hour 
2- Clearing stage: tissues were cleared in xylene: 
• Xylene            2 x 1 hour 





• Melted paraffin (58 οC)      2 X 1 hour 
8.1.3 Tissues Embedding in Paraffin Block 
 
After tissue processing, the tissue slices were embedded in wax block. This 
involved placement of the tissues in a metal moulding block. Melted wax was 
poured into the block using wax melting system (WD-4, Germany), and the 
block was cooled on a cold plate (CPL-4, Axel Johnson Lab system, 
Germany). Afterward, the moulding block was removed from the wax block 
which contains the tissue slice and ready for sectioning. 
8.2 Preparation of the Tissue Sections 
 
8.2.1 Tissue Sectioning 
 
The wax block which containing the tissue was sectioned using rotary 
microtome (Leica RM2125RT, Germany) into 6 µm thickness for IHC or 5 µm 
for H&E staining, and gently with untoothed forceps the sections were 
transferred into a dish containing 30% alcohol in distilled water. Then the 
sections transferred to a hot distilled water bath 43 οC (Leica H1210, 
Germany) using a glass slide to flatten the section. Then, sections were 
mounted on glass slide and stored at 60 οC in the oven overnight. 
8.2.2 Deparaffinization and Hydration of the Section 
  
Tissue sections were deparaffinized in xylene. whereas the sections 
transferred quickly from oven to xylene to facilitate de-waxing of the section. 
Then, sections were rehydrated into decreasing concentration of alcohol and 
rinsed in running tape water as follow: 
• xylene:                  3 x 5 min 
• 100% alcohol:       2 x 3 min 
• 96% alcohol:         2 x 2 min 
• 70% alcohol:         1 x 1 min 






8.3 Staining Protocol 
8.3.1 Immunohistochemistry Staining Protocol  
8. 3.1.1 Immunofluorescent Protocol 
 
• After hydration, the sections were washed with PBS for 5 min. 
• antigen retrieval: after wash in PBS the sections were treated with heat 
antigen retrieval using citrate buffer or Tris-EDTA. 
A. Preparation of Antigen Retrieval Buffer  
1) Preparation of citrate buffer (10 mM citric acid, 0.05% Tween 
20, pH 6.0) used for antigen retrieval 
                  Citric acid (anhydrous)          1.92 g 
                  Distilled water                         1 L 
Mix on stirrer until dissolve. Adjust pH to 6.0 then add 0.5 ml of tween 20 and 
mix well. Store at 4οC. 
2) Preparation of Tris-EDTA (10 mM tris base, 1 mM EDTA 
solution, 0.05% Tween 20, pH 9).  
                 Tris base             1.21 g 
                 EDTA                 0.37 g 
                 Distilled water     1 L  
Mix well and adjust pH to 9 then add 0.5 ml of Tween 20 and store at 4 οC. 
B. Heat induced antigen retrieval using pressure cooker 
 
1. The cooker was filed with distilled water to appropriate level and the 
antigen retrieval buffer (citrate buffer or Tris-EDTA) were poured into 
plastic coplin jar and placed into the cooker. 
2. The cooker was placed together with buffer on a hot plat and the lid 





3. The cooker was left to boil then the slides were transferred into 
container which containing the buffer and the lid was secured as 
manufacture’s instruction. As soon as the cooker reach maximum 
pressure the time was set for 5 or 20 min depend on the protocol. 
4. When the time have relapsed, hot plat was turned off and the cooker 
was transferred into sink containing water, the pressure release valve 
was activated and tap water ran over the cooker. Then the lid was 
opened and the slid container were transferred out of the cooker and 
left to cool at room temperature for 10 min.      
• Sections were washed with PBS/Tween-20 (3 times jet washes then 
wash for 5 min on the stirrer). 
• Sections were incubated into 50 mM ammonium chloride for 30 min to 
quench aldehyde induced auto-fluorescent to reduce back ground 
staining. 
• Sections were washed with PBS/ 0.1 % Tween-20 for 5 min. 
• Non-specific binding was blocked with 3% BSA in PBS/ 0.1% Triton 
X-100 for 2 hours at room temperature in humidity chamber. 
•  Slides were drained without rinse it and wiped around the section 
with tissue paper. 
• Sections were incubated with primary antibody overnight at 4 οC in 
humidity chamber. 
• Slides were drained and washed with PBS/Tween-20 for 15 min on 
stirrer. 
• Sections were incubated with secondary antibody CY3 either anti-
mouse CY3 1:1000 dilution in 1 % BSA in PBS or antirabbit CY3 
1:2000 dilution in 1% BSA in PBS in humidity chamber for 2 hours in 
dark at room temperature. 
• Sections were washed with PBS for 30 min in dark on stirrer. 
• Slides were drained and wiped around the section then were mounted 
with glycerol and coverslip. 
• Sections were kept in the dark until viewed with fluorescent 





8.3.1.2 Chromogenic Staining Protocol (final protocol) 
 
• After de-waxing and hydration of the sections.  
• Sections were rinsed in running water for 1 min. 
• Sections were washed with PBS for 5 min on stirrer. 
• Endogenous peroxidase was blocked by incubation of the sections in 
3% hydrogen peroxide in distilled water for 15 min on stirrer bar 
• Wash with PBS/Tween-20 jet wash 3 times then wash for 5 min on 
stirrer. 
• Section were incubated with 3% BSA in PBS/0.1% Triton X-100 to 
block non-specific binding for 1 hour at room temperature. 
• Slide were drained without rinse it and wiped around the section with 
tissue paper. 
• Sections were incubated with primary antibody; antirabbit anti-
syndecan-1 (1:500 dilution) diluted in 3% BSA in PBS with 0.1% Triton 
X-100 in humidity chamber overnight at 4 οC. 
• Sections were washed in PBS/Tween-20 for 5 min on stirrer. 
• Section were incubated with goat antirabbit secondary antibody 1:250 
were diluted in PBS with 1% BSA in humidity chamber at room 
temperature for 1 hour.  
• Wash again with PBS/Tween- 20 for 15 min on stirrer. 
• Sections were incubated with DAB substrate for 6 min then rinsed with 
double distilled water to stop the reaction. 
• Slide were drained and dehydrated in increasing concentration of 
alcohol 70%, 95% x 2, 100% x 2. Then cleared in two changes of 
xylene. 
• Mount with DPX and coverslips. 









8.3.2 Hematoxylin and Eosin (H&E) Staining Protocol. 
 
• Sections were de-waxed and hydrated in the same way were described 
for immunostaining.   
• Sections were rinsed in running tap water for 1 min. 
• Sections were stained with hematoxylin for 5 min. 
• Sections were rinsed in running tap water for 1 min. 
• Sections were blued in Scott’s water for 1 min. 
• Sections were rinsed in running tap water for 1 min. 
• Sections were countered stain with eosin for 15 second. 
• Sections were rinsed briefly in running water for <10 sec. 
• Section then were dehydrated in increasing concentration of alcohol 
(brief immersion with gentle agitation) as follow: 
o 70% alcohol x 2 
o 96% alcohol x 2 
o 100% alcohol x 2 
o Clearing in xylene x 2 
• The sections were stayed in the last xylol until ready to coverslip. 
• Section were mounted with Dibutyl phthalate-DPX (Sigma) and 
coverslip and leave to dry at room temperature before viewing under 
microscope. 
9. Quantification of the Extracellular Cellular Area Using 
Image J.  
 
 Open the picture in ImageJ. 
Image        type 8-bit  
Image brightness/ contrast  apply  
Image         threshold        analysis        set measurement       limit to threshold 
(limit to the extracellular area)  






10. A summary of the Statistical Data of Syndecan-1 Staining 
Intensity Scores and Difference Between Groups: control, 
ischemia followed by reperfusion (I/R), S1P treatment before ischemia 
(I/R+S1P) and S1P treatment without ischemia (S1P perfusion). 
 
 
11. A summary of Statistical Data of Quantification of Cardiac 
Edema and Difference Between Groups: control, ischemia followed 
by reperfusion (I/R), S1P treatment before ischemia (I/R+S1P) and S1P 





P value summary ***
Control I/R I/R+S1P S1P
Number of values 360 360 360 360
Mean 2.558 0.6556 0.5611 2.381
Std. Deviation 0.7328 0.7672 0.6564 0.7591
Std. Error 0.03862 0.04043 0.03459 0.04001
Dunn's Multiple Comparison TestSignificant? P < 0.05? Summary
Control vs I/R Yes ***
Control vs I/R+S1P Yes ***
Control vs S1P No ns
I/R vs I/R+S1P No ns
I/R vs S1P Yes ***
I/R+S1P vs S1P Yes ***
One-way analysis of variance
P value 0.0002
P value summary ***
Number of groups 4
Tukey's Multiple Comparison Test Significant? P < 0.05?Summary
Control vs I/R Yes ***
Control vs I/R+S1P No ns
Control vs S1P Perfuion No ns
I/R vs I/R+S1P Yes **
I/R vs S1P Perfuion Yes **
I/R+S1P vs S1P Perfuion No ns
Control I/R I/R+S1P S1P Perfuion
Number of values 54 54 54 54
Mean 37.06 43.48 37.43 37.96
Std. Deviation 7.027 7.849 7.081 11.24
Std. Error 0.9562 1.068 0.9636 1.529
APPENDICES 
106 
12. Ethics Committee Certificate Approved the Study
